Improved nasal administration of pharmaceutical formulations
By using a nasal spray device to administer a liquid corticosteroid drug composition intranasally, a plume with a specific droplet size distribution is formed, which solves the problem of low drug deposition efficiency in the nasal cavity, achieving more uniform drug coverage and better therapeutic effects.
Patent Information
- Application Number
- CN202380026134.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-24
- Filing Date
- 2023-01-05
- Publication Date
- 2024-11-22
AI Technical Summary
Existing nasal spray devices have low drug deposition efficiency in the nasal cavity, making them difficult to effectively treat diseases such as allergic rhinitis and nasal polyps, and the drug distribution is uneven.
A liquid drug composition containing corticosteroids is used and administered intranasally via a nasal spray device to form a plume with a specific droplet size distribution, ensuring that the drug evenly covers the surface area of the nasal cavity, including the nasal septum, nasal floor, and nasal lateral walls.
It improves the deposition efficiency and coverage area of drugs in the nasal cavity, enhances the therapeutic effect on diseases such as allergic rhinitis and nasal polyps, and achieves a more uniform drug distribution.
Smart Images

Figure CN119012999A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 297,060, filed on January 6, 2022, and U.S. Provisional Application No. 63 / 418,662, filed on October 24, 2022, the disclosures of which are incorporated herein by reference in their entireties.
[0003] Overview
[0004] Disclosed herein are methods of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) a corticosteroid, an ester thereof, or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some embodiments, the liquid pharmaceutical composition forms a plume comprising more than one droplet after intranasal administration to the subject by actuating a nasal spray device comprising the liquid pharmaceutical composition, the more than one droplet passing through a D 90 is characterized by a plume in which about 90% of the droplets have a diameter less than D 90 In some embodiments, administering an effective amount of the pharmaceutical composition can treat a disease or condition. In some embodiments, the more than one droplet can also be characterized by less than about 1.5% of the droplets in the plume having a size less than about 10 μm. In some embodiments, the more than one droplet can also be characterized by a D of about 23 μm to about 30 μm. 50 In some embodiments, about 50% of the droplets in the plume have a diameter less than D 50 In some embodiments, D 50It can be about 25 μm. In some embodiments, the droplet size can be measured by laser diffraction. In some embodiments, corticosteroids, their esters or salts thereof can include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, their esters, their salts or any combination thereof. In some embodiments, corticosteroids, their esters or salts thereof can include fluticasone or its salt. In some embodiments, the plume can be formed by the actuation of a nasal spray device, and lasts from about 0.5 seconds to about 5 seconds from the start of spraying to the end of spraying. In some embodiments, a pharmaceutically acceptable carrier can include water. In some embodiments, the liquid pharmaceutical composition can also include a viscosity enhancer. In some embodiments, the liquid pharmaceutical composition can also include an excipient. In some embodiments, the liquid pharmaceutical composition can also include a preservative. In some embodiments, the actuation can include an actuation amount of a liquid of about 10 μl to about 200 μl or from about 20 μl to about 80 μl. In some embodiments, intranasal administration can be once, twice, three times or four times a day to each nostril. In some embodiments, the plume can cover about 15% to about 50%, about 10% to about 80%, about 5% to about 90%, about 5% to about 100% of the surface area of the nasal cavity as measured by a nasal cast scan. In some embodiments, the nasal cavity may include the nasal septum, the nasal floor, the nasal side walls, the inferior nasal meatus, the middle nasal meatus, the superior nasal meatus, the olfactory cleft, the olfactory region, the turbinates, or any combination thereof. In some embodiments, the nasal cavity may include the nasal septum, the nasal floor, the nasal side walls, the inferior nasal meatus, the middle nasal meatus, the superior nasal meatus, the olfactory cleft, the olfactory region, and the turbinates. In some embodiments, the liquid pharmaceutical composition may be in a unit dose and may include about 10 μg to about 2000 μg of a corticosteroid, an ester thereof, or a salt thereof. In some embodiments, the disease or condition may include allergic rhinitis, nasal polyps, sinusitis, or any combination thereof. In some embodiments, the disease or condition may include symptoms of the disease or condition. In some embodiments, the symptoms of the disease or condition can include nasal congestion, sneezing, runny nose, itchy eyes, itchy nose, itchy throat, postnasal drip, fatigue, coughing, tearing, loss of smell, sore throat, snoring, headache, facial pain, nasal purulent drainage, fungal debris, malodor or any combination thereof. In some embodiments, the method can also include the administration of a second therapeutic agent. In some embodiments, the liquid pharmaceutical composition can also include a second therapeutic agent. In some embodiments, the second therapeutic agent can be administered simultaneously or continuously. In some embodiments, the second therapeutic agent can include a salt of any one of a PDE inhibitor, an antihistamine, a vasoconstrictor, a decongestant or these. In some embodiments, the second therapeutic agent can include sodium cromoglycate.In some embodiments, the method may further include diagnosing the subject with allergic rhinitis, nasal polyps, sinusitis, or any combination thereof. In some embodiments, the nasal spray device can deliver a plume as a unit dose after actuation. In some embodiments, the nasal spray device can contain about 60 to about 120 unit doses. In some embodiments, each unit dose can contain about 10 μg to about 2000 μg of a corticosteroid, an ester thereof, or a salt thereof. In some embodiments, the subject may be a subject in need thereof. In some embodiments, the subject may be a human. In some embodiments, after actuation, the nasal spray device can deliver about 35 mg to about 50 mg of a pharmaceutical composition. In some embodiments, more than one droplet can also pass through a D of about 14 μm to about 19 μm. 10 is characterized by a droplet density of less than D 10 In some embodiments, the stroke length of the actuation of the nasal spray device can be 4.6 mm, 4.8 mm, or 4.9 mm. In some embodiments, the actuator stroke speed of the actuation of the nasal spray device can be 2 mm / s or 3 mm / s. In some embodiments, the actuator stroke acceleration of the actuation of the nasal spray device can be about 500 mm / s 2 In some embodiments, the nasal spray device can have a nozzle aperture of about 3 μm, about 4 μm, or about 5 μm. In some embodiments, the nasal spray device can have about 40 to about 70 nozzle apertures or about 45 nozzle apertures to about 65 nozzle apertures. In some embodiments, the nasal spray device can have a cone angle of about 20 degrees.
[0005] Also disclosed herein is a nasal spray device comprising: a corticosteroid, an ester thereof, or a salt thereof. In some embodiments, the nasal spray device can be configured to deliver a dose unit in a plume upon actuation. In some embodiments, the dose unit can comprise a therapeutically effective amount of a corticosteroid, an ester thereof, or a salt thereof in a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some embodiments, the plume can have a droplet size distribution characterized by: (a) less than about 1.5% of the droplets in the plume have a size less than about 10 μm; and (b) a D of about 38 μm to about 49 μm. 90 In some embodiments, about 90% of the droplets in the plume may have a diameter less than D 90 Also disclosed herein is a kit comprising a nasal spray device and a container.
[0006] Also disclosed herein is a method of treating allergic rhinitis in a subject in need thereof, the method comprising administering a corticosteroid, an ester thereof, or a salt thereof using a nasal spray device, the nasal spray device delivering a dose unit in a plume upon actuation, the dose unit comprising a therapeutically effective amount of a corticosteroid, an ester thereof, or a salt thereof in a liquid pharmaceutical composition, the liquid pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, excipient, or any combination thereof. In some embodiments, the plume comprises droplets and has a droplet size distribution characterized by: (a) less than about 1.5% of the droplets in the plume have a size less than about 10 μm; and (b) a D of about 38 μm to about 49 μm. 90 In some embodiments, about 90% of the droplets in the plume may have a diameter less than D 90 size.
[0007] Also disclosed herein is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) an antihistamine or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some embodiments, the liquid pharmaceutical composition forms a plume comprising more than one droplet after intranasal administration to the subject by actuating a nasal spray device comprising the liquid pharmaceutical composition, wherein the more than one droplet passes through a D 90 to characterize the plume, where about 90% of the droplets in the plume can have a diameter less than D 90 In some embodiments, administering an effective amount of a pharmaceutical composition can treat a disease or condition. In some embodiments, the disease or condition can include allergies.
[0008] Also disclosed herein is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some embodiments, the liquid pharmaceutical composition forms a plume comprising more than one droplet after intranasal administration to the subject by actuating a nasal spray device comprising the liquid pharmaceutical composition, wherein the more than one droplet passes through a D 90 to characterize the plume, where about 90% of the droplets in the plume can have a diameter less than D 90 In some embodiments, administering an effective amount of a pharmaceutical composition can treat a disease or condition. In some embodiments, the disease or condition can include pain. In some embodiments, pain can include acute pain or chronic pain.
[0009] Also disclosed herein is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) an anticholinergic drug or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some embodiments, the liquid pharmaceutical composition forms a plume comprising more than one droplet after intranasal administration to the subject by actuating a nasal spray device comprising the liquid pharmaceutical composition, wherein the more than one droplet passes through a D 90 to characterize the plume, where about 90% of the droplets in the plume can have a diameter less than D 90 In some embodiments, administering an effective amount of the pharmaceutical composition can treat a disease or condition. In some embodiments, the disease or condition can include asthma, diarrhea, motion sickness, gastrointestinal disorders, overactive bladder, urinary incontinence, poisoning, muscle spasms, motion sickness, chronic obstructive pulmonary disease (COPD), hyperhidrosis, or any combination thereof.
[0010] Incorporated by Reference
[0011] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The novel features of the present disclosure are set forth, with particularity, in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by referring to the following detailed description of illustrative embodiments utilizing the principles of the present disclosure and the accompanying drawings, in which:
[0014] Figure 1 Images of the nasal model after spraying with a soft mist nasal spray device, a slow standard nasal spray device, and a standard nasal spray device are shown. Liquid formulations in the spray device were tested with and without a cellulose (i.e., carboxymethyl cellulose) viscosity enhancer. The soft mist nasal spray device deposited a greater amount of formulation in the olfactory region of the nasal model.
[0015] Figure 2 The nasal spray characteristics of three spray devices are shown: a soft mist nasal spray device, a slow standard nasal spray device, and a standard nasal spray device. Compared to the standard nasal spray having a spray containing larger particle diameters (i.e., the standard nasal spray and the slow standard nasal spray), the soft mist nasal spray device shows a spray distribution in which about 50% of the particles have a diameter of less than about 20 μm.
[0016] Figure 3A box and whisker graph is depicted showing the metered shot weight (amount released in milligrams (mg)) from a soft mist pump device at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s, and 4 mm / s (mm / s)) and at stroke lengths of 4.6 mm, 4.8 mm, and 4.9 mm.
[0017] Figure 4 Depicted are box and whisker plots showing the emission weight (amount delivered in mg) delivered from a soft mist pump device at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s, and 4 mm / s (mm / s)) and at stroke lengths of 4.6 mm, 4.8 mm, and 4.9 mm.
[0018] Figure 5 Box and whisker plots are depicted showing the plume geometry performance (plume angle (degrees) and plume width (mm)) at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s (mm / s)) and at a stroke length of 4.8 mm at a pattern distance of 60 mm from the soft mist pump device.
[0019] Figure 6 Box and whisker plots are depicted showing the spray patterns (Dmax (mm), Dmin (mm), ellipticity and area (mm^2)) at different actuation speeds (2 mm / s and 3 mm / s) and at a stroke length of 4.8 mm, at pattern distances of 30 mm and 60 mm from the soft mist pump device.
[0020] Figure 7 Depicted are images showing spray patterns at different actuation speeds (2 millimeters / second and 3 millimeters / second (mm / s)) and at pattern distances of 30 mm and 60 mm from a soft mist pump device (Device 12) at a 4.8 mm stroke length.
[0021] Figure 8 Box-and-whisker plots showing the droplet size distribution (% volume < 10 μm; span; D) at different actuation speeds (2 mm / s and 3 mm / s) and at a stroke length of 4.8 mm at 30 mm and 60 mm pattern distances from the soft mist pump device are depicted. 90 value (μm); and D 50 value (μm)).
[0022] Fig. 9 Box and whisker plots are depicted showing the plume geometry performance (plume angle (degrees) and plume width (mm)) at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s (mm / s)) and at 4.6 mm and 4.8 mm stroke lengths at a pattern distance of 60 mm from the soft mist pump device.
[0023] Fig.10 Box and whisker plots are depicted showing the spray patterns (Dmax (mm), Dmin (mm), ellipticity and area (mm^2)) at different actuation speeds (2 mm / s and 3 mm / s) and at 4.6 mm and 4.8 mm stroke lengths at a pattern distance of 30 mm from the soft mist pump device.
[0024] Fig.11 Box and whisker plots are depicted showing the spray patterns (Dmax (mm), Dmin (mm), ellipticity and area (mm^2)) at different actuation speeds (2 mm / s and 3 mm / s) and at 4.6 mm and 4.8 mm stroke lengths at a pattern distance of 60 mm from the soft mist pump device.
[0025] Fig.12 Box-and-whisker plots are depicted showing the droplet size distribution (% volume < 10 μm; span; D) at different actuation speeds (2 mm / s and 3 mm / s) and at 4.6 mm and 4.8 mm stroke lengths at a pattern distance of 30 mm from the soft mist pump device. 90 value (μm); and D 50 value (μm)).
[0026] Fig.13 Box and whisker plots are depicted showing the droplet size distribution (% volume < 10 μm; span; D) at different actuation speeds (2 mm / s and 3 mm / s) and at 4.6 mm and 4.8 mm stroke lengths at a pattern distance of 60 mm from the soft mist pump device. 90 value (μm); and D 50 value (μm)).
[0027] Details
[0028] definition
[0029] Unless otherwise defined, all technical terms, symbols, and other technical and scientific terms or terminology used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference from what is generally understood in the art.
[0030] Throughout this application, various embodiments can be presented in a range format. It should be understood that the description in range format is only for convenience and brevity and should not be interpreted as an unchangeable limitation to the scope of the present disclosure. Therefore, the description of the scope should be considered to have specifically disclosed all possible sub-ranges and the independent numerical values within the scope. For example, the description of the scope such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc. and the independent numerals such as 1, 2, 3, 4, 5 and 6 within the scope. Regardless of the width of the scope, this is applicable.
[0031] Unless the context clearly dictates otherwise, the singular forms "a," "an," and "the" include plural referents. Accordingly, unless indicated otherwise, the numerical parameters set forth in this application are approximations that may vary depending upon the desired properties sought to be obtained.
[0032] The terms "determine," "measure," "assess," "evaluate," "assay," and "analyze" are often used interchangeably herein to refer to forms of measurement and include determining whether an element may be present (e.g., detecting). These terms may include quantitative determinations and qualitative determinations. Assessments may alternatively be relative or absolute. "Detecting the presence of" includes determining the amount of something present, as well as determining whether it may be present or absent.
[0033] The term "substantially" or "essentially" refers to a qualitative condition that all or nearly all of the range or extent of a feature or characteristic of interest is exhibited. In some cases, substantially refers to at least about 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or 99.99% of the total range or extent of the feature or characteristic of interest. In some cases, substantially or essentially refers to an amount that can be about 100% of the total amount.
[0034] The term "at least in part" refers to a qualitative condition that exhibits a partial range or degree of a feature or characteristic of interest. In some cases, at least in part refers to at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% of the total range or degree of a feature or characteristic of interest.
[0035] Open terms such as "contain," "containing," "include," "including," and similar terms mean comprising unless otherwise stated.
[0036] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, according to the practice of the art, "about" means plus or minus 10%. Alternatively, "about" means a range of plus or minus 20%, plus or minus 10%, plus or minus 5%, or plus or minus 1% of a given value. Alternatively, particularly with respect to biological systems or biological processes, the term means within the order of magnitude of a value, within 5 times, or within 2 times. In the case of describing a particular value in the present application and claims, unless otherwise stated, the term "about" should be assumed to mean within an acceptable error range for a particular value. In addition, where a range and / or subrange of a value is provided, the range and / or subrange may include the endpoints of the range and / or subrange.
[0037] When used herein, the percentage of a compound of a composition is relative to the total weight or volume of the composition. In some cases, the percentage of a component of a composition is relative to the total weight or volume of the composition.
[0038] As used herein, the terms "administer", "administering", "administration" and similar terms refer to methods for enabling a compound or its salt or composition to be delivered to a desired biological site of action. Delivery can include direct application to an affected tissue or body area. The compositions provided herein can be administered by any method. The method of administration can be by nasal spray. In some cases, the method of administration can be by inhalation, intraarterial injection, intranasal administration, intraventricular injection, intracisternal injection, intramuscular injection, intraorbital injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection or any combination thereof. Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion), oral administration, nasal administration, inhalation administration, intraduodenal administration, rectal administration. Delivery can include topical application (such as lotions, creams, gels, liquids, solids, powders, ointments) to the outer surface of a surface (such as skin). In some cases, a subject applies an intranasal spray containing a compound without supervision. In some cases, the subject can administer the intranasal formulation under the supervision of a medical professional (e.g., a physician, nurse, physician assistant, caregiver, hospice staff, etc.). In some cases, a medical professional administers the intranasal formulation. In some cases, a cosmetic professional administers the intranasal formulation.
[0039] As used herein, "treatment" of a disease or condition includes one or more of the following: reducing the frequency or severity of one or more symptoms, preventing one or more symptoms or their underlying causes, eliminating one or more symptoms or their underlying causes, or ameliorating or remedying damage. For example, treatment of allergic rhinitis can include reducing the severity of the symptoms of allergic rhinitis, such as reducing nasal congestion, sneezing, runny nose, itchy eyes, itchy nose, itchy throat, postnasal drip, fatigue, coughing, tearing, loss of smell, loss of taste, sore throat, or snoring.
[0040] "Therapeutically effective amount" refers to an amount of a compound or salt thereof that is effective to achieve its intended purpose with or without additional agents. The needs of individual patients may vary. In general, the dosage required to provide an effective amount of a compound, a salt thereof, or a composition comprising one or both of these will vary depending on the recipient's age, health, physical condition, sex, weight, degree of dysfunction, frequency of treatment, and the nature and extent of the dysfunction.
[0041] As used herein, "dosage unit" refers to a discrete amount of a pharmaceutical composition administered in a single event or package. The meaning of the term dosage unit is context specific. For example, a dosage unit of a liquid pharmaceutical composition administered intranasally would be the volume of the composition administered in a single event. In some cases, for nasal sprays, the dosage unit would be the volume of the composition released each time the nasal spray device is actuated.
[0042] "Weight percent" or "w / w" means the ratio of the mass of a particular ingredient relative to the mass of the entire composition (eg, dosage unit).
[0043] "Plume geometry" or "geometry" when used in connection with a plume means a measure of the angle of the plume at its origin. The plume geometry can be measured at two distances from the plume origin, for example, at two side views at 90° relative to each other. The plume geometry can also be calculated from the spray pattern.
[0044] "Spray pattern", "plume ellipticity" or "ellipticity" when used in connection with a plume refers to the shape and size of the plume at a distance from its origin. "Ellipticity" can be measured as the ratio of the largest diameter to the smallest diameter.
[0045] “D 10 ”, “D 50 ”, “D 90 " and "span" are measures of the droplet or particle size distribution of a plume. In a plume, 10% of the droplets have a diameter smaller than D 10 50% of the droplets have a size smaller than D 50 size, and 90% of the droplets have a diameter smaller than D 90The span can be calculated from these numbers according to the following formula: Span = (D 90 -D 10 ) / D 50 In some cases, D 10 , D 50 or D 90 The value may be an average or median from more than one spray and / or droplet.
[0046] "Total volume" when used in connection with a plume refers to the combined volume of all droplets or particles in the plume. For example, a plume with a total volume of 100 μL contains 100 μL of liquid.
[0047] The terms "subject", "host", "individual" and "patient" are used interchangeably herein to refer to animals, typically mammals. Any suitable mammal can be administered a compound, salt or composition as described herein or treated by a method as described herein. Non-limiting examples of mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, macaques, etc.), domestic animals (e.g., dogs and cats), farm animals (e.g., horses, cattle, goats, sheep, pigs) and experimental animals (e.g., mice, rats, rabbits, guinea pigs). The mammal can be of any age or at any stage of development, for example, the mammal can be a newborn, infant, teenager, adult or in utero. In some embodiments, the mammal is a human. The human can be greater than about 1, 2, 5, 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115 or about 120 years old. The human can be less than about 1, 2, 5, 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or about 120 years old. In some cases, the human can be less than about 18 years old. In some cases, the human can be from about 1 month to about 12 months old, from about 1 year old to about 20 years old, from about 15 years old to about 50 years old, from about 40 years old to about 80 years old, or from about 60 years old to about 110 years old. In some cases, the human can be older than about 18 years old. Mammals such as humans can be male or female. In some embodiments, the subject can have or can be suspected of having a disease or condition such as allergic rhinitis, nasal polyps, sinusitis, or any combination thereof. The subject can be a patient, such as a patient who is being treated for a condition or disease, such as heart disease, hypertension, atrial fibrillation, stroke, allergic rhinitis, nasal polyps, sinusitis, renal failure, liver disease, cancer, diabetes, respiratory disease, asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, lung cancer, cystic fibrosis, coronavirus infection, influenza infection, viral infection, bacterial infection, fungal infection, parasitic infection, pneumonia, pleural effusion or any combination thereof. The subject may be prone to the risk of developing a condition or disease such as a respiratory disease. The subject may be in remission of a condition or disease, such as a cancer patient. In some cases, the subject may be healthy.
[0048] As disclosed herein, the term "phosphodiesterase (PDE) inhibitor" refers to a compound or a salt thereof that can at least partially inhibit the function of a PDE polypeptide (such as PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, PDE11 polypeptide or any combination thereof).
[0049] As used herein, reference to corticosteroids in general, a specific corticosteroid, or any pharmaceutically related compound includes reference to any salt, solvate, ester, or polymorph of the corticosteroid or compound. "Salt" may include pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts can include those prepared by reacting the compounds disclosed herein with mineral acids, organic acids or inorganic bases, such salts include acetates, acrylates, adipates, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bitartrate, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, hexanoate, octanoate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and xylenesulfonate. In addition, the compounds disclosed herein can be prepared as pharmaceutically acceptable salts by reacting the free base form of the compound with a pharmaceutically acceptable inorganic acid or organic acid, including but not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, Benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, l,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid.Other acids, such as oxalic acid, although not pharmaceutically acceptable per se, can be used to prepare salts that can be used as intermediates for obtaining compounds and / or pharmaceutically acceptable acid addition salts. In some embodiments, the compounds disclosed herein that may contain free acid groups react with suitable bases (such as hydroxides, carbonates, bicarbonates, sulfates) of pharmaceutically acceptable metal cations, react with ammonia, or react with pharmaceutically acceptable organic primary amines, secondary amines or tertiary amines. Representative alkali metal salts or alkaline earth metal salts may include lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts and aluminum salts and similar salts. Illustrative examples of alkalis may include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(C1-4 alkyl)4 and the like. Representative organic amines that can be used to form base addition salts may include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It is understood that the compounds disclosed herein may also include quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water-soluble products or oil-soluble products or dispersible products can be obtained by such quaternization. The compounds disclosed herein can be prepared as pharmaceutically acceptable salts, which are formed when the acidic protons present in the parent compound can be replaced by metal ions (e.g., alkali metal ions, alkaline earth metal ions, or aluminum ions); or coordinated with organic bases. In some embodiments, base addition salts can also be prepared by reacting the free acid form of the compounds disclosed herein with a pharmaceutically acceptable inorganic base or organic base, which includes, but is not limited to: organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like; and inorganic bases such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide and the like. In addition, the salt forms of the disclosed compounds can be prepared using salts of starting materials or intermediates.
[0050] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0051] Overview
[0052] Disclosed herein are methods, compositions, kits, and devices for treating a disease or condition with a corticosteroid, an ester thereof, or a salt thereof. In some cases, the disease or condition may include allergic rhinitis, nasal polyps, sinusitis, or any combination thereof. In some embodiments, the method of treatment may include administering a corticosteroid, an ester thereof, a salt thereof, or a combination of corticosteroids to a subject via a nasal spray device. The nasal spray device may release a dosage unit in a plume upon actuation. In some embodiments, the nasal spray device is configured to release D 50The value is about 20 μm plume. In some cases, the corticosteroid, its ester or salt thereof can be administered as an intranasal formulation. In some cases, the corticosteroid can include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, its salt or any combination thereof.
[0053] Corticosteroids and other therapeutic agents
[0054] Disclosed herein are corticosteroids, their esters and their salts for the treatment of diseases or conditions.Corticosteroids are steroid hormones or synthetic analogs of steroid hormones that can act as agonists of glucocorticoid receptors and / or mineralocorticoid receptors.In some cases, corticosteroids can have anti-inflammatory, immunosuppressive, antiproliferative and vasoconstrictive effects.In some cases, corticosteroids can block the effects of inflammatory mediators and induce anti-inflammatory mediators.In some cases, the immunosuppressive effects of corticosteroids can be mediated by suppressing delayed hypersensitivity reactions.In some cases, the antiproliferative effects of corticosteroids can be mediated by suppressing DNA synthesis and epidermal cell renewal.In some cases, the vasoconstrictive effects of corticosteroids can be mediated by suppressing inflammatory mediators such as histamine.Compositions disclosed herein, such as nasal sprays, comprise corticosteroids or their salts, and are administered to subjects with corresponding needs.
[0055] In some cases, the corticosteroid can comprise an ester of a corticosteroid. In some cases, the corticosteroid can include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, a salt thereof, or any combination thereof.
[0056] In some cases, corticosteroids can include natural corticosteroids, synthetic corticosteroids, or both. In some cases, natural corticosteroids can include 11-dehydrocorticosterone (11-oxocorticosterone, 17-deoxycortisone), 11-deoxycorticosterone (deoxycortone, deoxycorticosterone; 21-hydroxyprogesterone), 11-deoxycortisol (deoxycortisone, deoxycortisone (cortexolone)), 11-ketoprogesterone (11-oxoprogesterone; ketogestin), 11β-hydroxypregnenolone, 11β-hydroxyprogesterone (21-deoxy hydroxycorticosterone, 17α,21-trihydroxypregnenolone, 17α,21-dihydroxypregnenolone, 17α-hydroxypregnenolone, 17α-hydroxyprogesterone, 18-hydroxy-11-deoxycorticosterone, 18-hydroxycorticosterone, 18-hydroxyprogesterone, 21-deoxycortisol, 21-deoxycortisone, 21-hydroxypregnenolone (prebediolone), aldosterone, corticosterone (17-deoxycortisol), cortisol (hydrocortisone), cortisone, pregnenolone, progesterone, salts of any of these, or any combination thereof.
[0057] In some cases, the synthetic corticosteroid can comprise a progestin-type corticosteroid, a hydrocortisone-type corticosteroid, a methasone-type corticosteroid, an acetonide-type corticosteroid, or any combination thereof.
[0058] In some cases, the progestin-type corticosteroid can include flugestone, flurogestone, fluorometholone, medrysone, prebediolone, salts of any of these, or any combination thereof.
[0059] In some cases, the hydrocortisone-type corticosteroid can include cloprednisone, clopredniol, difluprednate, fludrocortisone, fluocinolone, fluperolone, fluprednisolone, loteprednol, methylprednisolone, prednicarbate, prednisolone, prednisone, tixocortol, triamcinolone acetonide, salts of any of these, or any combination thereof.
[0060] In some cases, the methasone-type corticosteroid can include alclometasone, beclomethasone, betamethasone, clobetasol, clobetasone, clocortolone, desoximetasone, dexamethasone, diflorasone, difluocortolone, fluclorololone, flumethasone, fluocortolone, fluprednidene, fluticasone, fluticasone furoate, halometasone, methylprednisone, mometasone, mometasone furoate, paramethasone, prednylidene, rimexolone, ubetasol (halobetasol), a salt of any of these, or any combination thereof.
[0061] In some cases, the acetonide-type corticosteroid can include amcinonide, budesonide, ciclesonide, deflazacort, desonide, formocort (flucloronide), fluclorolone acetonide (flucloronide), fludroxycortide (flurandrenolone, flurandrenolide), flunisolide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, a salt of any of these, or any combination thereof.
[0062] In some cases, the corticosteroid can include cortisol, RU-28362 (6-methyl-11β,17β-hydroxy-17α-(1-propynyl)androsta-1,4,6-trien-3-one), a salt thereof, or any combination thereof.
[0063] In some cases, the corticosteroid can include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, salts thereof, or any combination thereof.
[0064] In some cases, corticosteroids can include dexamethasone intensol, florinef acetate, prednisone intensol, triamcinolone acetonide acetate, cortisone acetate, fluticasone furoate, fluticasone propionate, mometasone furoate, beclomethasone dipropionate, triamcinolone acetonide acetate, or any combination thereof.
[0065] In some cases, the corticosteroid can include a corticosteroid ester. In some cases, the corticosteroid ester can be an ester of a natural corticosteroid. In some cases, esters of natural corticosteroids can include deoxycorticosterone acetate, deoxycorticosterone cypionate, deoxycorticosterone enanthate, deoxycorticosterone glucoside, deoxycorticosterone pivalate, benzohydrocortisone, hydrocortisone acetate propionate, hydrocortisone acetate, hydrocortisone bendazac, hydrocortisone butyrate propionate, hydrocortisone butyrate, hydrocortisone 21-butyrate, hydrocortisone cypionate, hydrocortisone phosphate, hydrocortisone succinate, hydrocortisone terbutalate, hydrocortisone valerate, hydrocortisone xanthate, 11-dehydrocorticosterone acetate, cortifen (deoxycortisone chlorophenacyl ester), cortisone acetate, corticosterone acetate, corticosterone benzoate, deoxycortisone acetate, or any combination thereof.
[0066] In some cases, the corticosteroid ester can be an ester of a synthetic corticosteroid. In some cases, the ester of a synthetic corticosteroid can include beclomethasone dipropionate, beclomethasone salicylate, beclomethasone acetate valerate, betamethasone acetate, betamethasone acibutate, betamethasone adamantane, betamethasone benzoate, betamethasone dipropionate, betamethasone divalerate, betamethasone phosphate, betamethasone succinate, betamethasone valerate, betamethasone acetate valerate, cortobenzolone, clocortolone acetate, clocortolone caproate, clocortolone pivalate, dexamethasone furate, dexa ... acefurate), dexamethasone acetate, dexamethasone sibetic acid, dexamethasone diethylaminoacetic acid, dexamethasone dipropionate, dexamethasone isonicotinate, dexamethasone linoleate, dexamethasone meta-sulfobenzoate, dexamethasone palmitate, dexamethasone phosphate, dexamethasone pivalate, dexamethasone succinate, dexamethasone sulfate, dexamethasone terbutalate, dexamethasone trisomate, dexamethasone valerate, ciprocinonide, fluocinolone acetate, procinonide, fluocortin, fluocortin butyl ester butyl), fluocortolone caproate, fluocortolone pivalate, fluprednisolone acetate, fluprednisolone succinate, fluprednisolone valerate, methylprednisolone acetate propionate, methylprednisolone acetate, methylprednisolone cypionate, methylprednisolone phosphate, methylprednisolone succinate, methylprednisolone sulfoheptanoate, prednazate, prednazoline, prednicarbate, prednimustine, prednisolamate, prednisolone acetate, prednisolone caproate, prednisolone meta-sulfobenzoate, palm prednisolone phosphate, prednisolone piperidine acetate, prednisolone pivalate, prednisolone steaglate, prednisolone stearoyl glycolate, prednisolone succinate, prednisolone sulfate, prednisolone terbutate, prednisolone tetrahydrophthalate, prednisolone valerate, prednisolone acetate valerate, prednisone acetate, prednisone palmitate, prednisone succinate, tixocortolone butyrate, tixocortolone propionate, tixocortolone pivalate, triamcinolone acetate menagate, triamcinolone acetate phosphate, triamcinolone acetate succinate, triamcinolone benetonide, triamcinolone furetonide, triamcinolone hexylhexacetonide), delta-7-prednisolone 21-acetate, alclometasone dipropionate, amcinonide, chlorprednisolone acetate, ciclometasone, clobetasol propionate, clobetasone butyrate, clopredniol acetate, cormethasone acetate, cortivazole, clothiocarbone propionate, deflazacort, diprotone propionate, desonide phosphate, desonide pivalate, dichlorosone acetate, dichlorosone diacetate, diflorasone diacetate, difluorosone pivalate Corone, diflucortolone valerate, difluprednisolone acetate butyrate, dimethasone acetate, hydroxycinonide phosphate, etiprednol diacetate, fluazacort, fludrocortisone acetate, flumethasone acetate, flumethasone pivalate, flunisolide acetate, fluorometholone acetate, fluperolone acetate, fluprednidine acetate, fluticasone furoate, fluticasone propionate, formocort, halopednisolone acetate, icometasone acetate enbutate, isoflurane acetate, locicrotolone dicibate, loteprednol etabonate, methylclosanone dibutyrate, methylprednisone acetate, methylprednisone succinate, mometasone furoate, nicocortonide, nicocortonide acetate, paramethasone acetate, paramethasone phosphate, prebediolone acetate, prednisone diethylaminoacetate, rofleponide palmitate, ticabesone propionate, timobesone acetate, ampicillin isobutyrate, triamcinolone acetonide diacetate, ubetasol propionate, or any combination thereof.
[0067] In some embodiments, the compositions herein may include an antihistamine, a decongestant, a vasoconstrictor, or any combination thereof. In some cases, the antihistamine may include nitrogen. In some cases, the composition herein may include amphetamine, antihistamine, caffeine, ergonovine, naphazoline, oxymetazoline, phenylephrine, propylhexedrine, pseudoephedrine, tetrahydrozoline, any of these salts or any combination thereof. In some cases, the composition herein may include amphetamine, antihistamine, caffeine, ergonovine, naphazoline, oxymetazoline, phenylephrine, propylhexedrine, pseudoephedrine, tetrahydrozoline, any of these salts or any combination thereof. In some cases, the composition herein may include a mast cell stabilizer. In some cases, the compositions herein may include a cromolyn, such as sodium cromolyn.
[0068] In some embodiments, the composition herein may include nonsteroidal anti-inflammatory drugs (NSAIDs). In some cases, NSAIDs may include salicylates, propionic acid derivatives, acetic acid derivatives, enolic acid derivatives, anthranilic acid derivatives, selective COX-2 inhibitors or sulfonanilides. In some cases, salicylates may include acetylsalicylic acid (aspirin), diflunisal (Dolobid), salicylic acid, salsalate, any of these salts or any combination thereof. In some cases, propionic acid derivatives may include ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, pelubiprofen (pelubiprofen), zaltoprofen (zaltoprofen), any of these salts or any combination thereof. In some cases, acetic acid derivatives can include indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, bromfenac, nabumetone, any salt of these or its any combination. In some cases, enoic acid derivatives can include piroxicam, meloxicam, tenoxicam, droxicam (droxicam), lornoxicam, isoxicam (isoxicam), phenylbutazone (phenylbutazone), any salt of these or its any combination. In some cases, anthranilic acid derivatives can include mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, any salt of these or its any combination. In some cases, selective COX-2 inhibitors can include celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib, any salt of these or its any combination. In some cases, sulfonanilides can include nimesulide or its salt. In some cases, the NSAID may include clonixin, lexafilon, harpagside, salts of any of these, or any combination thereof.
[0069] In some embodiments, the compositions herein may comprise an anticholinergic. In some embodiments, the anticholinergic may comprise thioridazine, haloperidol, olanzapine, a salt of any of these, or any combination thereof. In some cases, the anticholinergic can include amitriptyline, atropine, aclidinium bromide, benztropine, chlorpheniramine, chlorpromazine, clomipramine, clozapine, cyclobenzaprine, cyproheptadine, darifenacin, desipramine, dexchlorpheniramine, dicyclomine, diphenhydramine, doxepin, hydroxyzine, scopolamine, imipramine, meclizine, nortriptyline, olanzapine, o-phenadrine, oxybutynin, paroxetine, perphenazine, prochlorperazine, promethazine, protriptyline, pseudoephedrine hcl / triprolidine hcl, scopolamine, thioridazine, tolterodine, trifluoperazine, trihexyphenidyl, trimipramine, a salt of any of these, or any combination thereof.
[0070] Compositions and preparations
[0071] In some embodiments, compositions or preparations described herein may include active ingredients, carriers, excipients, viscosity enhancers, diluents, preservatives, enzyme regulators, vasoconstrictors, mucoadhesives, wetting agents or any combination thereof. In some cases, carriers, excipients, viscosity enhancers, diluents, preservatives, wetting agents, enzyme regulators, vasoconstrictors or mucoadhesives may be pharmaceutically acceptable forms thereof. In some cases, active ingredients may include corticosteroids, esters or salts thereof as described herein. For example, corticosteroids may include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, esters thereof, salts thereof or any combination thereof. In some cases, carriers may include water. In some cases, viscosity enhancers may include cellulose. In some embodiments, compositions or preparations described herein may be liquids. In some cases, excipients may include glycerol. In some cases, compositions or preparations described herein may be delivered by nasal spray devices. In some cases, compositions herein may be sterile. In some cases, the compositions herein can be sterile (aseptic).
[0072] In some cases, the preparation or composition can include an activating agent, such as a corticosteroid, an ester thereof, or a salt thereof. In some cases, the composition or preparation can include an activating agent in an amount greater than about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% (wt / wt) of the total composition. In some cases, a composition or formulation may contain an active agent in an amount of less than about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% (wt / wt) of the total composition. In some cases, compositions or preparations can include about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% (wt / wt) of the total composition The amount of the activating agent. In some cases, compositions or preparations can include about 0.01% to about 10% (wt / wt) of the total composition The amount of the activating agent. In some cases, a composition or formulation may include one active agent. In some cases, a composition or formulation may include more than one active agent, for example, a composition may include 2, 3, 4, 5 or more active agents.
[0073] In some embodiments, compositions or preparations may include excipients. In some cases, excipients may be pharmaceutically acceptable excipients. Excipients may include, but are not limited to, water, fluidizing agents, lubricants, adhesives, surfactants, acidulants, alkalizers, agents for adjusting pH, antimicrobial preservatives, antioxidants, antistatic agents, buffers, chelating agents, wetting agents or wetting agents. Excipients may also include colorants, coating agents, sweeteners, flavoring agents and aromatics or masking agents. Compositions and preparations may include therapeutic agents with a single excipient or with a variety of excipients in any suitable combination, with or without carriers. In some cases, excipients may include glycerol.
[0074] In some cases, the pharmaceutically acceptable excipients can include gum arabic, acesulfame potassium, acetic acid, glacial acetic acid, acetone, acetyl tributyl citrate, acetyl triethyl citrate, agar, albumin, alcohol, alginic acid, fatty polyester, alitame, almond oil, alpha tocopherol, aluminum hydroxide adjuvant, aluminum oxide, aluminum phosphate adjuvant, aluminum stearate, ammonia solution, ammonium alginate, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butyl paraben, calcium alginate, calcium carbonate, calcium phosphate, dibasic anhydrous, calcium phosphate, dibasic dihydrate, calcium tribasic phosphate, phosphate, tribasic), calcium stearate, calcium sulfate, rapeseed oil, carbomer, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, castor oil, hydrogenated castor oil, cellulose (e.g., microcrystalline cellulose, powdered cellulose, silicified microcrystalline cellulose, cellulose acetate, cellulose acetate phthalate), carob bean gum, cetearyl alcohol, cetyl trimethylamine bromide, cetyl alcohol, cetylpyridinium chloride, chitosan, chlorhexidine, chlorobutanol, chlorocresol, chlorodifluoride Ethane, chlorofluorocarbons, chloroxylenol, cholesterol, citric acid monohydrate, colloidal silicon dioxide, colorant, copovidone, corn oil, cottonseed oil, cresol, croscarmellose sodium, crospovidone, cyclodextrin, cyclomethicone, denatonium benzoate, dextran, dextrin, dextrose, dibutyl phthalate, dibutyl sebacate, diethanolamine, diethyl phthalate, difluoroethane, dimethicone, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, disodium ethylenediaminetetraacetate , docusate sodium, ethylenediaminetetraacetic acid, isoascorbic acid, erythritol, ethyl acetate, ethyl lactate, ethyl maltol, ethyl oleate, ethyl vanillin, ethyl cellulose, ethylene glycol palmitostearate, ethylene vinyl acetate, ethyl paraben, fructose, fumaric acid, gelatin, glucose, glycerin, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, tetraethylene glycol ether (glycofurol), guar gum, hectorite, heptafluoropropane, hexamethylenetetrafluoroethylene Hepidine, hydrocarbons, hydrochloric acid, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, hydroxypropyl starch, hypromellose, hypromellose acetate succinate, hypromellose phthalate, honey, imidazolidinyl urea, inulin, iron oxide, isomalt, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, kaolin, lactic acid, lactitol, anhydrous lactose, monohydrated lactose, spray-dried lactose, lanolin, lanolin alcohol, hygroscopic lanolin,Lauric acid, lecithin, leucine, linoleic acid, polyethylene glycol hydroxystearate, aluminum magnesium silicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate, malic acid, maltitol, maltitol solution, maltodextrin, maltol, maltose, mannitol, medium chain triglycerides, meglumine, menthol, methylcellulose, methylparaben, mineral oil, light mineral oil, monoethanolamine, monosodium glutamate, monothioglycerol, myristic acid, neohesperidin dihydrochalcone, nitrogen, nitrous oxide, octyldodecanol, oleic acid, oleyl alcohol, olive oil, palmitic acid, paraffin, peanut oil, pectin, petrolatum, phenol, Phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, phosphoric acid, polacrilin potassium, poloxamer, polycarbophil, polydextrose, polyethylene glycol, polyethylene oxide, polymethacrylate, poly(methyl vinyl ether / maleic anhydride), polyoxyethylene alkyl ether, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, polyvinyl acetate phthalate, polyvinyl alcohol, potassium alginate, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabisulfite, potassium sorbate, povidone, propionic acid, propyl gallate, propylene carbonate, propylene glycol, sea Propylene glycol alginate, propylparaben, 2-pyrrolidone, raffinose, saccharin, saccharin sodium, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium alginate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium chloride, sodium citrate dihydrate, sodium cyclamate, sodium hyaluronate, sodium hydroxide, sodium lactate, sodium lauryl sulfate, sodium metabisulfite, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium propionate, sodium starch glycolate, sodium stearyl fumarate, sodium sulfite, sorbic acid, sorbitan esters (sorbitan fatty acid esters), sorbitol, soybean oil, starch, starch (e.g., pregelatinized, sterilizable corn, stearic acid, stearyl alcohol, sucralose, sucrose, sugar, compressible sugar, candy, sugar spheres, sulfobutyl ether beta-cyclodextrin, sulfuric acid, sunflower oil, suppository base, hard fat, talc, tartaric acid, tetrafluoroethane, sweet protein, thimerosal, thymol, titanium dioxide, tragacanth gum, trehalose, triacetin, tributyl citrate, triethanolamine, triethyl citrate, vanillin, hydrogenated vegetable oil, water, wax, anionic emulsifier, wax (e.g., carnauba wax, cetyl esters, microcrystalline, nonionic emulsifier, white wax, yellow wax), xanthan gum, xylitol, zein, zinc acetate, zinc stearate, or any combination thereof.
[0075] In some embodiments, the composition or formulation may include a viscosity enhancer (e.g., a solution thickener). In some cases, the viscosity enhancer may include cellulose. In some cases, the viscosity enhancer may include carboxymethyl cellulose (CMC), cellulose I, cellulose II, cellulose III, cellulose IV, microcrystalline cellulose (MCC), sodium carboxymethyl cellulose (NaCMC), or a combination thereof. In some cases, the viscosity enhancer may include cellulose acetate, cellulose triacetate, cellulose propionate, cellulose acetate propionate, cellulose acetate butyrate, methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (HPC), hydroxyethyl methylcellulose, ethyl hydroxyethyl cellulose, hydroxypropyl methylcellulose, or a combination thereof. In some cases, the composition or formulation may include a viscosity enhancer in an amount of about 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (wt / wt) of the total composition. In some cases, the composition or formulation may include a viscosity enhancer in an amount of about 0.01% to about 10% (wt / wt) of the total composition. In some cases, the composition or formulation may include one viscosity enhancer. In some cases, the composition or formulation may include more than one viscosity enhancer, for example, the composition may include 2, 3, 4, 5 or more viscosity enhancers.
[0076] In some cases, the viscosity of the intranasal dosage unit can affect the residence time in the nasal cavity. In some embodiments, the dosage unit has a higher kinematic viscosity than water at the same temperature. In some embodiments, the dosage unit can have a kinematic viscosity of from 0.5 cSt to 3 cSt at 20°C. For example, the dosage unit can have 0.5-2 cSt, 0.5-1.5 cSt, 0.5-1.25 cSt, 0.5-1.1 cSt, 0.5-1 cSt, 0.5-0.9 cSt, 0.5-0.75 cSt, 0.75-2 cSt, 0.75-1.5 cSt, 0.75-1.25 cSt, 0.75-1.1 cSt, 0.75-1 cSt, 0.75-0.9 cSt, 0 In some embodiments, the dosage unit has a kinematic viscosity of 0.9-2 cSt, 0.9-1.5 cSt, 0.9-1.25 cSt, 0.9-1.1 cSt, 0.9-1 cSt, 1-2 cSt, 1-1.5 cSt, 1-1.25 cSt, 1-1.1 cSt, 1.1-2 cSt, 1.1-1.5 cSt, 1.1-1.25 cSt, 1.25-2 cSt, 1.25-1.5 cSt, 1.5-2 cSt, or 2-3 cSt. In some embodiments, the dosage unit has a kinematic viscosity of 0.9-1.25 cSt at 20° C. In some embodiments, the dosage unit has a higher kinematic viscosity than water at the same temperature.
[0077] In some embodiments, the composition or preparation may include a carrier. In some cases, the carrier may include water, such as purified water. In some cases, the carrier may include a saline solution. In some cases, the carrier for the composition or preparation includes but is not limited to amino acids, peptides, proteins, non-biological polymers, biopolymers, monosaccharides, carbohydrates, gums, inorganic salts and metal compounds, which may exist alone or in combination. In some embodiments, a pharmaceutically acceptable carrier may include a natural form, a derived form, a modified form or a combination thereof. In some cases, a protein may include but is not limited to gelatin or albumin. In some embodiments, sugars that may be used as carriers include but are not limited to fructose, galactose, glucose, lactitol, lactose, maltitol, maltose, mannitol, melezitose, inositol, palatinose (palatinite), raffinose, stachyose, sucrose, trehalose, xylitol, hydrates thereof and combinations thereof. In some cases, carbohydrates that may be used as carriers include but are not limited to starch, such as corn starch, potato starch, amylose, amylopectin, pectin, hydroxypropyl starch, carboxymethyl starch and cross-linked starch. In other embodiments, useful carbohydrates that may be used as pharmaceutically acceptable carriers include, but are not limited to, cellulose, crystalline cellulose, microcrystalline cellulose, alpha-cellulose, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and cellulose acetate. In some cases, a composition or formulation may comprise about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54% of the total composition. In some cases, the composition or preparation can include about 60% to about 99.9% (wt / wt) of the total composition. In some cases, the composition or formulation may include a carrier.In some cases, the composition or formulation may include more than one carrier, for example, the composition may include 2, 3, 4, 5 or more carriers. In some cases, the carrier may include a non-aqueous carrier. In some cases, the non-aqueous carrier may include a solvent, an excipient, a vehicle, a permeation enhancer (also referred to as a penetration enhancer), or a mixture thereof.
[0078] In some cases, the compositions herein can be aqueous or non-aqueous formulations. In some cases, the benefits of non-aqueous solution formulations can be 1) there may be no need to include preservatives, and 2) there may be a potential higher drug load in the formulation due to the potential higher solubility of PDE inhibitors such as theophylline in a variety of non-aqueous excipients / vehicles, for example, the solubility of theophylline in water is about 7-8 mg / mL, while the solubility of theophylline in ethanol is 14-15 mg / mL.
[0079] In some embodiments, the excipient, vehicle (such as carrier) or both for non-aqueous preparation (replacing water) can include alkylene glycol, such as propylene glycol, butylene glycol or its any combination. In some cases, the excipient, vehicle (such as carrier) or both for non-aqueous preparation can include dialkylene glycol (such as, dipropylene glycol). In some cases, the excipient, vehicle (such as carrier) or both for non-aqueous preparation can include polyethylene glycol (PEG) (such as, PEG400, PEG600 or its any combination). In some cases, the excipient, vehicle (such as carrier) or both for non-aqueous preparation can include unsaturated fatty alcohol, such as palm oil alcohol, oleyl alcohol, erucic acid alcohol or its any combination. In some cases, the excipient, vehicle (such as carrier) or both for non-aqueous preparation can include DMSO, Transcutol P (diethylene glycol monoethyl ether), ethanol, acetone or its any combination.
[0080] In some embodiments, the composition or formulation may include a diluent. In some cases, the diluent may include an excipient. In some cases, the diluent may include water, saline, buffer, sugar, binder, disintegrant, or any combination thereof.
[0081] In some embodiments, the composition or preparation may include a preservative. In some cases, the preservative may include alcohol. In some cases, the preservative may include phenylethyl alcohol. In some cases, the preservative may include methylparaben, propylparaben, benzalkonium chloride, benzyl alcohol, potassium sorbate or a combination thereof. In some cases, the composition disclosed herein may be preservative-free. In some cases, the composition or preparation may include about 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4% or 5% (wt / wt) of the total composition of the preservative. In some cases, the composition or formulation may include a preservative in an amount of about 0.01% to about 10% (wt / wt) of the total composition. In some cases, the composition or formulation may include one preservative. In some cases, the composition or formulation may include more than one preservative, for example, the composition may include 2, 3, 4, 5 or more preservatives.
[0082] In some embodiments, the composition or formulation may include a buffer. In some cases, the buffer may include potassium phosphate, sodium acetate, sodium citrate, sodium phosphate, trisodium citrate, or a combination thereof. In some cases, the composition or formulation may include a pH adjusting agent, such as acetic acid, citric acid, hydrochloric acid, sodium hydroxide, sulfuric acid, or a combination thereof.
[0083] In some embodiments, the pH of the composition or formulation may be from 7.1 to 8.5. In some cases, the pH may be from 7.1 to 7.4. In some embodiments, the pH of the composition or formulation may be 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the pH of the composition or formulation may be at least 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the pH of the composition or formulation may be from 6 to 7. In some embodiments, the pH of the composition or formulation may be 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7. In some embodiments, the pH of the dosage unit can be from 7.1 to 8.5. In some embodiments, the pH of the dosage unit can be from 7.1 to 7.4. In some embodiments, the pH of the dosage unit can be 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the pH of the dosage unit can be at least 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, or 8.5.
[0084] In some embodiments, the composition or preparation may include glycerol. In some cases, the composition or preparation may include flavoring agents such as menthol, artificial flavors (e.g., strawberry, fruit flavors, mint flavors), natural flavors, saccharin sodium, sorbitol, or a combination thereof. In some cases, the composition or preparation may include a fluorescent agent (e.g., a fluorophore). Fluorescent agents can be used for nasal cast scanning. Some examples of fluorescent agents include Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 561, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 750, BODIPY FL, Coumarin, Cy3, Cy5, Fluorescein (FITC) Oregon Green, Pacific Blue, Pacific Green, Pacific Orange, PE-Cyanine 7, PerCP-Cyanine 5.5, Tetramethylrhodamine (TRITC), Texas Red, Efluor 450, Efluor 506, Efluor 660, PE-Efluor 610, PerCP-Efluor 710, APC-Efluor 780, Super Bright 436, super bright 600, super bright 645, super bright 702, super bright 780, cyan fluorescent protein (CFP), green fluorescent protein (GFP), red fluorescent protein (RFP), or any combination thereof.
[0085] In some embodiments, the composition or formulation may include a humectant. In some cases, the humectant may include glycerol, propylene glycol, hexylene glycol, butylene glycol, triacetin, vinyl alcohol, neoagarobiose, glycerol, sorbitol, xylitol, maltitol, polydextrose, quillaja sylvatica, lactic acid, urea or aloe.
[0086] In some embodiments, the compositions disclosed herein are stable in a freezer (e.g., -80°C to about -20°C), a refrigerator (e.g., 4°C), or at room temperature. In some cases, the compositions described herein can be stored in a container. For example, the container holds the pharmaceutical composition of the spray device. In some cases, the container is glass, plastic, metal, or any solid material. In some cases, the container is included in a kit. In some cases, when a sealed container holding a composition described herein is placed at about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C or 38°C and in a room atmosphere with a relative humidity of about 50% or about 40%-60%, after 3 months, 6 months or 12 months, the composition can retain greater than about 40%, 50%, 60%, 70%, 80%, 90% or 99% of the active ingredient or a salt thereof as measured by high performance liquid chromatography (HPLC).
[0087] In some embodiments, compositions described herein or preparation can include penetration enhancers. In some cases, penetration enhancers can be materials that can promote drug penetration into skin, mucous membrane, nerve sheath or through another barrier (e.g., mucous membrane tissue). In some cases, penetration enhancers can be at least partially: inert, nontoxic, nonirritating, non-allergic, compatible with medicine and excipient, odorless, tasteless, colorless or any combination thereof. In some cases, penetration enhancers can be fatty acids, alcohols, surfactants, solvents, hydrogen bond receptors or any combination thereof. In some cases, the penetration enhancer can include azone (1-dodecylazacycloheptane-2-one), dimethyl sulfoxide, dimethylacetamide, dimethylformamide, ethanol, propylene glycol, N-methylpyrrolidone, oleic acid, lauryl alcohol, ketone terpenes, terpenes, sulfoxides, alkanols, organic acids, alcohols, polyols, pyrrolidone, glycols, urea and urea derivatives, enzymes, iminosulfurane, cyclodextrin, fatty acid esters, surfactants, polymers, glyceryl monooleate, oxazolone or any combination thereof. In some cases, the penetration enhancer can include cyclodextrin, sodium hyaluronate, cremophor RH40, chitosan, cyclopentyl adenosine, dextran or any combination thereof. In some cases, the preparation herein can include an enzyme regulator.
[0088] In some embodiments, compositions or preparations can include the penetration enhancer of the amount from about 0.1% to about 20% weight / weight (wt / wt) of the total composition. In some cases, compositions or preparations can include the penetration enhancer of the amount from about 1% to about 10%, 2% to about 8%, 5% to about 15%, 4% to about 12% or 10% to about 20% (wt / wt) of the total composition. In some cases, compositions or preparations can include the penetration enhancer of the amount from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% (wt / wt) of the total composition. In some cases, the composition or formulation may include one penetration enhancer. In some cases, the composition or formulation may include more than one penetration enhancer, for example, the composition or formulation may include 2, 3, 4, 5 or more different penetration enhancers.
[0089] In some embodiments, the composition or formulation can include benzalkonium chloride, dextrose, microcrystalline cellulose, phenylethyl alcohol, polysorbate 80, purified water, sodium carboxymethylcellulose, disodium edetate, hydrochloric acid, sodium hydroxide, butylated hydroxytoluene, citric acid, citric acid monohydrate, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 20, propylene glycol, sodium citrate dihydrate, sorbitol, polysorbates, dispersible cellulose, glycerin, sodium citrate, cellulose, sodium carboxymethylcellulose, hypromellose, potassium sorbate, or any combination thereof.
[0090] In some cases, the enzyme regulator can include a p-glycoprotein inhibitor, a CYP450 inhibitor, an acetazolamide inhibitor, or any combination thereof. In some cases, the preparation herein can include a vasoconstrictor. In some cases, the vasoconstrictor can include phenylephrine or its salt. In some cases, the preparation can include a mucoadhesive. In some cases, the mucoadhesive can include chitosan, a derivative of chitosan, carboxymethyl cellulose, polyacrylic acid, or any combination thereof. In some cases, the preparation herein can include a ciliostatic. In some cases, the ciliostatic can include chlorobutanol, hydroxybenzoate, chlorocresol edetate, phenylmercuric acetate, thimerosal, any of these salts, or any combination thereof.
[0091] Nasal spray device
[0092] Disclosed herein is a device for administering an active ingredient for treating a disease or condition in a subject, such as a human. In some embodiments, the device can be used to administer a nasal spray to a subject in need thereof. In some embodiments, the device administers a plume of droplets upon actuation. In some cases, the plume of droplets can comprise a dosage unit. For example, a drug dosage unit can be administered by the device described herein. In some cases, the droplets can be referred to as particles. Upon actuation, the plume can deliver the droplets to the nasal cavity. In some embodiments, the spray can be configured to deposit the droplets in the olfactory region of the nasal cavity. The spray device disclosed herein can emit particles having a size of about 10 μm to about 20 μm.
[0093] In some embodiments, the nasal spray device delivers a plume as a unit dose upon actuation. In some cases, the nasal spray device includes about 60 to about 120 unit doses. In some cases, the nasal spray device includes about: 1 to about 200 unit doses, 10 to about 250 unit doses, 5 to about 50 unit doses, 50 to about 100 unit doses, 20 to about 220 unit doses, or about 100 to about 240 unit doses. In some cases, each unit dose may contain about 20 μg to about 4000 μg of an active ingredient such as a corticosteroid.
[0094] In some embodiments, the nasal spray device may include a spray nozzle. In some cases, the spray nozzle may be configured to produce a plume. In some cases, the nasal spray device may include one spray nozzle. In some cases, the nasal spray device may include multiple spray nozzles to produce a plume, for example, the spray device may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more nozzles to produce a plume. In some cases, the spray nozzle may modify the droplet parameters so that a droplet size range may be obtained. In some cases, the droplet size range may increase or decrease the amount of drug deposited in the nasal cavity. In some cases, the droplet size range may increase or decrease the amount of drug covered in the nasal cavity. In some cases, the droplet size range may increase or decrease the amount of drug in the area of the nasal cavity. For example, a droplet size range that deposits most of the drug in the olfactory area of the nasal cavity may be obtained. In some embodiments, the nasal spray device may include one or more dosage units. In some cases, the nasal spray device may include a reservoir having more than one dosage unit. In some embodiments, the spray device can emit a spray having a D 10 , D 50 , D 90 In some cases, a droplet size or particle size measurement (e.g., D 10 , D 50 or D90 The value) can be determined by a laser diffraction system. For example, the Malvern Spraytec system.
[0095] In some embodiments, the spray device may include one or more nozzle holes. In some cases, the spray device may include a nozzle aperture of about 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm or 10 μm. In some cases, the spray device may include a nozzle aperture of 3 μm. In some cases, the spray device may include a nozzle aperture of 4 μm. In some cases, the spray device may include a nozzle aperture of 5 μm. In some cases, the spray device may include about 10 to about 200 nozzle holes, about 10 to about 100 nozzle holes, about 10 to about 60 nozzle holes, about 20 to about 80 nozzle holes, about 30 to about 100 nozzle holes, about 40 to about 70 nozzle holes, about 45 to about 65 nozzle holes, or about 48 holes to about 60 nozzle holes. In some cases, the spray device may include about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75 nozzle holes. In some cases, the spray device may include 60 nozzle holes. In some cases, the spray device may include 48 holes. In some cases, the spray device may include a cone angle for applying the spray at a given angle. In some cases, the cone angle of the spray device may be about 10 ° to about 80 °, about 10 ° to about 60 °, about 10 ° to about 40 °, about 10 ° to about 30 °, about 15 ° to about 25 ° or about 20 ° to about 40 °. In some cases, the cone angle of the spray device can be about: 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 11°, 12°, 13°, 14°, 15°, 16°, 17°, 18°, 19°, 20°, 21°, 22°, 23°, 24°, 25°, 26°, 27°, 28°, 29°, 30°, 31°, 32°, 33°, 34°, 35°, 36°, 37°, 38°, 39° In some cases, the cone angle of the spray device can be about 20°.
[0096] In one example, the spray device may have 60 nozzle holes with a size of 4 μm per hole and a cone angle of 20°. In another example, the spray device may have 48 nozzle holes with a size of 5 μm per hole and a cone angle of 20°. In another example, the spray device may have 60 nozzle holes with a size of 5 μm per hole and a cone angle of 20°. In another example, the spray device may have 48 nozzle holes with a size of 4 μm per hole and a cone angle of 20°.
[0097] In some embodiments, the volume of the dosage unit can be from about 25 μL to about 2000 μL. In some embodiments, the spray device herein can include a single dosage unit or can include multiple dosage units. For example, the spray device described herein can be a multi-dose spray unit. In some cases, the actuation of the spray device can distribute a certain volume of dosage units. In some cases, the volume of the dosage unit can be from about 50 μL to about 400 μL. In some cases, the volume of the dosage unit can be from about: 20 μL to about 80 μL, 40 μL to about 300 μL, 60 μL to about 350 μL, 80 μL to about 450 μL, 100 μL to about 600 μL, 250 μL to about 600 μL, 500 μL to about 1 mL, 750 μL to about 1.5 mL or about 1 mL to about 2 mL. In some cases, the volume of a dosage unit can be about: 20 μL, 21 μL, 22 μL, 23 μL, 24 μL, 25 μL, 26 μL, 27 μL, 28 μL, 29 μL, 30 μL, 31 μL, 32 μL, 33 μL, 34 μL, 35 μL, 36 μL, 37 μL, 38 μL, 39 μL, 40 μL, 41 μL, 42 μL, 43 μL, 44 μL, 45 μL, 46 μL, 47 μL, 48 μL, 49 μL, 50 μL, 51 μL, 52 μL, 53 μL, 54 μL, 55 μL, 56 μL, 57 μL, 58 μL L, 59μL, 60μL, 61μL, 62μL, 63μL, 64μL, 65μL, 66μL, 67μL, 68μL, 69μL, 70μL, 71μL, 72μL, 73μL, 74μL, 75μL, 76μL, 77μL, 78μL, 79μL , 80μL, 81μL, 82μL, 83μL, 84μL, 85μL, 86μL, 87μL, 88μL, 89μL, 90μL, 91μL, 92μL, 93μL, 94μL, 95μL, 96μL, 97μL, 98μL, 99μL or 100μL.In some cases, the volume of the dosage unit can be about: 100 μL, 110 μL, 120 μL, 130 μL, 140 μL, 150 μL, 160 μL, 170 μL, 180 μL, 190 μL, 200 μL, 210 μL, 220 μL, 230 μL, 240 μL, 250 μL, 260 μL, 270 μL, 280 μL, 290 μL, 300 μL, 310 μL, 320 μL, 330 μL , 340μL, 350μL, 360μL, 370μL, 380μL, 390μL, 400μL, 410μL, 420μL, 430μL, 440μL, 450μL, 460μL, 47 0μL, 480μL, 490μL, 500μL, 510μL, 520μL, 530μL, 540μL, 550μL, 560μL, 570μL, 580μL, 590μL or 600μL. In some cases, the volume of a dosage unit can be about: 600 μL, 700 μL, 800 μL, 900 μL, 1000 μL, 1100 μL, 1200 μL, 1300 μL, 1400 μL, 1500 μL, 1600 μL, 1700 μL, 1800 μL, 1900 μL, or 2000 μL.
[0098] In some embodiments, the liquid drug composition can be administered in the form of a plume from actuation of the device. In some embodiments, the dosage unit can be in the form of a plume having a droplet size distribution characterized by one or more of the following: (a) less than about 3% of the droplets in the plume have a size less than about 10 μm, (b) a D value less than about 15 μm, 10 , where about 10% of the droplets in the plume have a diameter less than D 10 size, (c) D from about 15 to about 24 μm 50 , where about 50% of the droplets in the plume have a diameter less than D 50 The size of (d) is from about 30 μm to about 50 μm. 90 , where about 90% of the droplets in the plume have a diameter less than D 90 , and (e) a span from about 1 to about 4, wherein the span is calculated according to: (D 90 -D 10 ) / D 50 .
[0099] In some embodiments, the dosage unit may be in the form of a plume having a droplet size distribution characterized by one or more of the following: (a) less than about 1.5% of the droplets in the plume have a size less than about 10 μm, (b) a D value less than about 20 μm, 10, where about 10% of the droplets in the plume have a diameter less than D 10 (c) D from about 23 μm to about 30 μm 50 , where about 50% of the droplets in the plume have a diameter less than D 50 The size of (d) is from about 38 μm to about 48 μm. 90 , where about 90% of the droplets in the plume have a diameter less than D 90 , and (e) a span from about 0.9 to about 1.4, wherein the span is calculated according to: (D 90 -D 10 ) / D 50 .
[0100] In some embodiments, a plume may be characterized by less than about 4% of the droplets in the plume having a size less than about 10 μm. In some embodiments, a plume may be characterized by less than about 3% of the droplets in the plume having a size less than about 10 μm. In some embodiments, a plume may be characterized by less than about 2% of the droplets in the plume having a size less than about 10 μm. In some embodiments, a plume may be characterized by less than about 1.5% of the droplets in the plume having a size less than about 10 μm. In some embodiments, a plume may be characterized by less than about 1% of the droplets in the plume having a size less than about 10 μm. In some embodiments, the plume droplets may be measured based on the total amount of droplets in the plume. In some embodiments, the plume droplets may be measured based on the total volume of droplets in the plume.
[0101] In some embodiments, a plume may be characterized by less than about 3% of the droplets in the plume having a size less than about 5 μm. In some embodiments, a plume may be characterized by less than about 2% of the droplets in the plume having a size less than about 5 μm. In some embodiments, a plume may be characterized by less than about 1% of the droplets in the plume having a size less than about 5 μm. In some embodiments, a plume may be characterized by less than about 0.5% of the droplets in the plume having a size less than about 5 μm. In some embodiments, a plume may be characterized by less than about 0.25% of the droplets in the plume having a size less than about 5 μm. In some embodiments, a plume may be characterized by substantially all droplets in the plume or all droplets being larger than about 5 μm. In some embodiments, plume droplets may be measured based on the total amount of droplets in the plume. In some embodiments, plume droplets may be measured based on the total volume of droplets in the plume.
[0102] In some embodiments, D 10 About 10% of the droplets in the plume have a diameter less than D 10 In some embodiments, the plume may be formed by a D that may be less than about 20 μm. 10In some embodiments, the plume may be characterized by a D that may be less than about 15 μm. 10 In some cases, the plume may be characterized by a D that may be from about 10 μm to about 20 μm. 10 In some cases, the plume may be characterized by a D that may be from about 8 μm to about 15 μm. 10 In some cases, the plume may be characterized by a D that may be from about 12 μm to about 19 μm. 10 In some cases, the plume may be characterized by a D that may be about: 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 16 μm, 17 μm, 18 μm, 19 μm, or 20 μm. 10 In some cases, the plume may be characterized by a D that may be greater than about: 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 16 μm, 17 μm, 18 μm, 19 μm, or 20 μm. 10 To characterize.
[0103] In some embodiments, D 50 About 50% of the droplets in the plume have a diameter less than D 50 In some embodiments, the plume may have a D of from about 15 μm to about 24 μm. 50 In some embodiments, the plume may be characterized by a D of from about 10 μm to about 20 μm. 50 In some embodiments, the plume may be characterized by a D of from about 20 μm to about 30 μm. 50 In some embodiments, the plume may be characterized by a D of from about 23 μm to about 30 μm. 50 In some embodiments, the plume may be characterized by a D that may be about: 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 16 μm, 17 μm, 18 μm, 19 μm, 20 μm, 21 μm, 22 μm, 23 μm, 24 μm, 25 μm, 26 μm, 27 μm, 28 μm, 29 μm, 30 μm, 31 μm, 32 μm, or 33 μm. 50 To characterize.
[0104] In some embodiments, D 90 About 90% of the droplets in the plume have a diameter less than D 90 In some embodiments, the plume may be smaller than about 65 μm in diameter. 90 In some embodiments, the plume may be characterized by a D that may be less than about 60 μm. 90In some embodiments, the plume may be characterized by a D that may be less than about 50 μm. 90 In some embodiments, the plume may be characterized by a D that may be less than about 40 μm. 90 In some embodiments, the plume may be characterized by a D that may be less than about 35 μm. 90 In some embodiments, the plume may be characterized by a D that may be less than about: 60 μm, 59 μm, 58 μm, 57 μm, 56 μm, 55 μm, 54 μm, 53 μm, 52 μm, 51 μm, 50 μm, 49 μm, 48 μm, 47 μm, 46 μm, 47 μm, 46 μm, 45 μm, 44 μm, 43 μm, 42 μm, 41 μm, 40 μm, 39 μm, 38 μm, 37 μm, 36 μm, 35 μm, 34 μm, 33 μm, 32 μm, 31 μm, 30 μm, 29 μm, or 28 μm. 90 In some embodiments, the plume can be characterized by a D 90 , or less than about 42 μm D 90 In some embodiments, the plume may be characterized by a D 90 In some embodiments, the plume may be characterized by a D of from about 50 μm to about 60 μm. 90 In some embodiments, the plume may be characterized by a D of from about 45 μm to about 55 μm. 90 In some embodiments, the plume may be characterized by a D of from about 30 μm to about 50 μm. 90 In some embodiments, the plume may be characterized by a D of from about 40 μm to about 50 μm. 90 In some embodiments, the plume may be characterized by a D of from about 38 μm to about 49 μm. 90 In some embodiments, the plume may be characterized by a D of from about 35 μm to about 45 μm. 90 In some embodiments, the plume may be characterized by a D of from about 30 μm to about 40 μm. 90 In some embodiments, the plume may be characterized by a D of from about 25 μm to about 35 μm. 90In some embodiments, the plume may be characterized by a D that may be about: 28 μm, 29 μm, 30 μm, 31 μm, 32 μm, 33 μm, 34 μm, 35 μm, 36 μm, 37 μm, 38 μm, 39 μm, 40 μm, 41 μm, 42 μm, 43 μm, 44 μm, 45 μm, 46 μm, 47 μm, 48 μm, 49 μm, 50 μm, 51 μm, 52 μm, 53 μm, 54 μm, 55 μm, 56 μm, 57 μm, 58 μm, 59 μm, 60 μm, 61 μm, 62 μm, 63 μm, 64 μm, or 65 μm. 90 To characterize.
[0105] In some embodiments, the plume may be characterized by a span that may be from about 1 to about 5. In some embodiments, the plume may be characterized by a span that may be from about 1 to about 4. In some embodiments, the plume may be characterized by a span that may be from about 1 to about 3. In some embodiments, the plume may be characterized by a span that may be from about 1 to about 2. In some embodiments, the plume may be characterized by a span that may be from about 0.5 to about 1. In some embodiments, the plume may be characterized by a span that may be from about 0.5 to about 1.5. In some embodiments, the plume can be characterized by a span that can be about: 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.7, 29, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, or 6.
[0106] In some embodiments, the plume can be characterized by having an ellipticity of, for example, from about 0.5 to about 2. In some embodiments, the plume can be characterized by having an ellipticity of from about 0.5 to about 1. In some embodiments, the plume can be characterized by having an ellipticity of from about 0.8 to about 1.5. In some embodiments, the plume can be characterized by having an ellipticity of from about 1 to about 1.5. In some embodiments, the plume can be characterized by having an ellipticity of from about 1.1 to about 1.8. In some embodiments, the plume can be characterized by having an ellipticity of about: 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0.
[0107] In some embodiments, the plume can be characterized by having a geometry (e.g., a plume angle) from about 10° to about 90°. In some embodiments, the plume can be characterized by having a geometry from 45° to 75°. In some embodiments, the plume can be characterized by having a geometry from 20° to 45°. In some embodiments, the plume can be characterized by having a geometry from 15° to 40°. In some embodiments, the plume can be characterized by having a geometry from 25° to 40°. In some embodiments, the plume can be characterized by having a geometry of about: 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or 90°.
[0108] In some embodiments, the plume can be characterized by having a plume width from about 10 mm to about 90 mm. In some embodiments, the plume can be characterized by having a plume width from 45 mm to 75 mm. In some embodiments, the plume can be characterized by having a plume width from 20 mm to 45 mm. In some embodiments, the plume can be characterized by having a plume width from 15 mm to 40 mm. In some embodiments, the plume can be characterized by having a plume width from 25 mm to 40 mm. In some embodiments, the plume can be characterized by having a plume width of about: 10 mm, 15 mm, 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 45 mm, 50 mm, 55 mm, 60 mm, 65 mm, 70 mm, 75 mm, 80 mm, 85 mm, or 90 mm.
[0109] In some cases, the plume can be characterized by having a maximum diameter (Dmax) of the spray of about 10 mm to about 60 mm. In some cases, the plume can be characterized by having a Dmax of about 10 mm to about 50 mm. In some cases, the plume can be characterized by having a Dmax of about 10 mm to about 40 mm. In some cases, the plume can be characterized by having a Dmax of about 10 mm to about 30 mm. In some cases, the plume can be characterized by having a Dmax of about 10 mm to about 20 mm. In some cases, the plume can be characterized by having a Dmax of about 15 mm to about 20 mm. In some cases, the plume can be characterized by having a Dmax of about 16 mm to about 20 mm. In some cases, the plume can be characterized by having a Dmax of about 20 mm to about 50 mm. In some cases, the plume can be characterized by having a Dmax of about 30 mm to about 45 mm. In some cases, the plume can be characterized by having a Dmax of about 30 mm to about 50 mm. In some embodiments, the plume may be characterized by having a Dmax of about: 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm, 26 mm, 27 mm, 28 mm, 29 mm, 30 mm, 31 mm, 32 mm, 33 mm, 34 mm, 35 mm, 36 mm, 37 mm, 38 mm, 39 mm, 40 mm, 41 mm, 42 mm, 43 mm, 44 mm, 45 mm, 46 mm, 47 mm, 48 mm, 49 mm, 50 mm, 51 mm, 52 mm, 53 mm, 54 mm, 55 mm, 56 mm, 57 mm, 58 mm, 59 mm, or 60 mm.
[0110] In some cases, the plume can be characterized by having a minimum diameter of spray (Dmin) of about 10 mm to about 40 mm. In some cases, the plume can be characterized by having a Dmin of about 10 mm to about 30 mm. In some cases, the plume can be characterized by having a Dmin of about 10 mm to about 20 mm. In some cases, the plume can be characterized by having a Dmin of about 10 mm to about 15 mm. In some cases, the plume can be characterized by having a Dmin of about 20 mm to about 35 mm. In some cases, the plume can be characterized by having a Dmin of about 25 mm to about 35 mm. In some cases, the plume can be characterized by having a Dmin of about 21 mm to about 32 mm. In some embodiments, the plume may be characterized by having a Dmin of about: 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm, 26 mm, 27 mm, 28 mm, 29 mm, 30 mm, 31 mm, 32 mm, 33 mm, 34 mm, 35 mm, 36 mm, 37 mm, 38 mm, 39 mm, or 40 mm.
[0111] In some embodiments, the plume may be formed by having a diameter from about 100 mm. 2 To about 1500mm 2 In some embodiments, the plume can be characterized by having a plume area from 500 mm 2 Up to 1200mm 2 In some embodiments, the plume can be characterized by having a plume area from 600 mm 2 Up to 1300mm 2 In some embodiments, the plume can be characterized by having a plume area from 150 mm 2 Up to 200mm 2 In some embodiments, the plume can be characterized by having a plume area from 100 mm 2 Up to 500mm 2 In some embodiments, the plume may be characterized by having a plume area of about: 100 mm 2 , 200mm 2 、300mm 2 , 400mm 2 , 500mm 2 、600mm 2 、700mm 2 , 800mm 2 , 900mm 2 , 1000mm 2、1100mm 2 , 1200mm 2 、1300mm 2 、1400mm 2 or 1500mm 2 The plume area is used to characterize the
[0112] In some embodiments, the spray device can have an actuation time, which can be from the beginning of the spray to the end of the spray. In some cases, the spray device can have an actuation time of 0.5 seconds to about 5 seconds. In some cases, the spray device can have an actuation time of about 3 seconds. In some cases, the spray device can have an actuation time of about: 0.5 seconds, 1 second, 1.5 seconds, 2 seconds, 2.5 seconds, 3 seconds, 3.5 seconds, 4 seconds, 4.5 seconds or about 5 seconds. In some cases, the increase of the actuation time can increase the amount of the spray deposited on the olfactory area.
[0113] In some embodiments, the spray device can have an actuation length. In some cases, the actuation length can be about: 4mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm, 4.8mm, 4.9mm, 5mm, 5.1mm, 5.2mm, 5.3mm, 5.4mm or 5.5mm. In some cases, the actuation length can be about 4.6mm, 4.8mm or 4.9mm.
[0114] In some embodiments, the spray device can have a speed of about: 100 mm / s 2 (mm / s 2 )、200mm / s 2 、300mm / s 2 , 400mm / s 2 , 500mm / s 2 、600mm / s 2 , 700mm / s 2 , 800mm / s 2 , 900mm / s 2 or 1000mm / s 2 In some cases, the actuation stroke acceleration of the spray device may be about 500 mm / s. 2 .
[0115] In some embodiments, the spray device can have an actuation stroke speed of about: 0.5 millimeters per second (mm / s), 1 mm / s, 2 mm / s, 3 mm / s, 4 mm / s, 5 mm / s, 6 mm / s, 7 mm / s, 8 mm / s, 9 mm / s, or 10 mm / s. In some cases, the spray device can have an actuation stroke speed of about: 1 mm / s, 2 mm / s, 3 mm / s, or 4 mm / s.
[0116] In some cases, the spray device can have an average retention time of about 300 milliseconds (ms), 400ms, 500ms, 600ms, 700ms, 800ms, 900ms, or 1000ms. In some cases, the spray device can have an average retention time of about 684ms.
[0117] In some cases, the spray device can deliver the emission weight at each actuation. In some cases, the emission weight delivered can be about 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg or 100mg for each actuation. In some cases, the emission weight delivered can be about 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg or 60mg for each actuation. In some cases, the delivered shot weight may be about 45 mg or within about: 10%, 15%, 20%, or 25% of 45 mg.
[0118] In some cases, the spray device can deliver the emission weight of metering at each actuation. In some cases, the emission weight of metering can be about: 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg or 100mg for each actuation. In some cases, the emission weight of metering can be about: 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg or 60mg for each actuation. In some cases, the metered shot weight may be about 45 mg or within about: 10%, 15%, 20%, or 25% of 45 mg.
[0119] In some cases, the spray device can be tested by an automated system. In some cases, the spray device can be primed prior to testing. For example, the spray device can be actuated several times to ensure that the spray device contains a full dose prior to testing. In some cases, the characteristics of the spray (e.g., plume) can be determined at a distance. In some cases, the characteristics of the plume can be determined at about: 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, 60 mm, 70 mm, 80 mm, 90 mm, or 100 mm. In some cases, the characteristics of the plume can be determined at about 30 mm or about 60 mm.
[0120] Treatment
[0121] Disclosed herein are methods for treating a disease or condition in a human being. In some cases, a disease or condition may include allergic rhinitis, nasal polyps, sinusitis, or any combination thereof. In some cases, the compositions of the disclosure as described herein may be used to treat upper respiratory tract infections, croup, sore throats, and infectious diseases such as mononucleosis. In some cases, treating a disease or condition may include treating the symptoms of a disease or condition. For example, the symptoms of a disease or condition may include nasal congestion, sneezing, runny nose, itchy eyes, itchy nose, itchy throat, postnasal drip, fever, pain (such as facial pain), ear swelling, ear pressure, earache, fatigue, coughing, tearing, loss of smell, sore throat, snoring, headache, nasal purulent drainage, fungal debris, malodor, or any combination thereof. In some cases, the compositions herein may include treating the symptoms of allergic rhinitis. In some embodiments, the method of treatment may include applying a nasal spray to a subject in need thereof. In some cases, disclosed herein are methods for restoring normal chemosensory function in a subject suffering from chemosensory dysfunction. In some cases, the subject may have a chemosensory dysfunction associated with a disease described herein, such as allergic rhinitis, nasal polyps, and / or sinusitis. In some cases, the chemosensory dysfunction may be caused at least in part by a viral infection (e.g., coronavirus infection (COVID-19) and / or influenza infection), or may occur during or after a viral infection (e.g., coronavirus infection (COVID-19) and / or influenza infection). In some cases, the method may include administering to the subject a therapeutically effective amount of a corticosteroid, an ester thereof, or a salt thereof, to treat a disease or condition or a symptom thereof described herein. In some cases, a corticosteroid, an ester thereof, or a salt thereof may be administered in the form of an intranasal preparation, such as a spray that is formulated to deposit droplets containing a corticosteroid into the nasal cavity. In some cases, a corticosteroid, an ester thereof, or a salt thereof may be administered in a unit dose form in a preparation.
[0122] In some embodiments, the nasal spray device herein can provide enhanced delivery of therapeutic agents by bypassing the blood-brain barrier (BBB). The therapeutic agent used herein can travel to the CNS by passing through the epithelium in the olfactory region (OR) and moving to the olfactory bulb along the olfactory nerve, or moving to the pons along the lateral respiratory region and the trigeminal nerve. In some cases, the trigeminal nerve neuron terminal may only be present in the lower region of the epithelium and may not be directly exposed to the nasal cavity. Olfactory neuron cell bodies may be present in the epithelium, and their cilia can directly reach the nasal cavity. In some cases, therapeutic agents disclosed herein can be transported to the CNS by intracellular transport mechanisms, such as therapeutic agents being internalized by neurons at epithelial sites, transported along axons, and exocytosis in the CNS. In some cases, therapeutic agents disclosed herein can be transported through the epithelium via paracellular transport. In some cases, therapeutic agents disclosed herein enter the CNS through systemic circulation. In some cases, therapeutic agents disclosed herein can be transported to the CNS by extracellular transport mechanisms, such as therapeutic agents moving along the fluid in the space where they run to the CNS by neurons.
[0123] In some cases, the compositions of the present disclosure as described herein can be used to treat subjects suffering from allergic rhinitis, nasal polyps, sinus infections, or any combination thereof. In some cases, the compositions of the present disclosure can be used to treat the symptoms of diseases or conditions described herein. In some cases, allergic rhinitis can include hay fever. In some cases, allergic rhinitis can include seasonal rhinitis, such as seasonal allergic rhinitis can include spring, summer, autumn or winter rhinitis. In some cases, rhinitis can include allergies to mold spores, pollen, grass, weeds, trees or other plants. In some cases, allergic rhinitis can include perennial rhinitis. In some cases, rhinitis can include allergies to dust mites, pet hair, dander, cockroaches, mold, dust, dander, smoke (e.g., cigarette smoke), perfume, exhaust (e.g., diesel exhaust) or any combination thereof. In some embodiments, diseases or conditions can include allergies. In some cases, allergies can include drug allergies, food allergies, insect allergies, latex allergies, mold allergies, pet allergies, pollen allergies, or combinations thereof.
[0124] In some cases, symptoms of a disease or condition disclosed herein (e.g., allergic rhinitis or sinusitis) can include stuffy nose, nasal congestion, congestion, runny nose, post nasal drainage, post nasal drip, itchy nose, itchy mouth, itchy eyes, itchy throat, sore throat, red eyes, tearing, mucus accumulation in the eyes, inflammation (e.g., inflammation of the eyes, sinuses, nose), eyelid edema, eyelid swelling, sneezing, earache, ear pressure, fever, cough, fatigue, honeycomb, loss of smell, loss of taste, snoring, headache, or any combination thereof. In some cases, symptoms of a disease or condition disclosed herein (e.g., nasal polyps) can include runny nose, persistent nasal congestion, polyps, abnormal growths in the nasal cavity, nasal congestion, post nasal drip, post nasal drainage, loss of smell, loss of taste, facial pain, headache, upper tooth pain, pressure on the forehead and / or face, snoring, nosebleeds, or any combination thereof.
[0125] In some cases, the disease or condition may include nasal polyps. In some cases, nasal polyps are noncancerous. In some cases, nasal polyps are cancerous. In some cases, the nasal polyps may be ethmoid nasal polyps. In some cases, the nasal polyps may be antrochoanal nasal polyps. In some cases, ethmoid polyps may occur in the ethmoid sinuses. In some cases, ethmoid polyps may extend into the nasal cavity through the middle nasal meatus. In some cases, an antrochoanal nasal polyp may occur in the maxillary sinus. In some cases, an antrochoanal nasal polyp may extend into the nasal cavity.
[0126] In some cases, the disease or condition may include sinusitis. In some cases, sinusitis may include a sinus infection. In some cases, sinusitis may include infectious sinusitis, allergic sinusitis, air pollution sinusitis, or nasal structural problems. In some cases, sinusitis may include viral sinusitis, bacterial sinusitis, fungal sinusitis, or a combination thereof.
[0127] In some embodiments, the compositions herein can be used to treat pain. In some cases, pain can be inflammation. For example, the corticosteroids or NSAIDs herein can be used to treat inflammation. In some cases, the compositions herein can be used to treat arthritis, such as osteoarthritis, rheumatoid arthritis, gout, fibromyalgia, childhood arthritis or any combination thereof. In some cases, pain can be chronic pain or acute pain. In some cases, pain can include headache, pain period, muscle sprain, muscle strain, cold, flu, arthritis, surgical pain, postoperative pain, muscle pain, fracture pain, oral pain, neuropathic pain, nociceptive pain, radicular pain or any combination thereof. In some cases, pain can be lacerations or injuries of the skin, burns, muscle injuries, tendon injuries, skin injuries, bone injuries, pregnancy, labor of a pregnancy, delivery of a pregnancy, pregnancy recovery, diabetic peripheral neuropathic pain, complex regional pain syndrome or any combination thereof. In some cases, the compositions herein can be used to treat pain from fibromyalgia, arthritis, diabetes, herniated disc, cancer, chronic migraines, pinched nerves, sciatica, heart attack, stroke, shingles, post-herpetic neuralgia, trigeminal neuralgia, or any combination thereof.
[0128] In some embodiments, the compositions herein can be used to treat asthma, diarrhea, motion sickness, gastrointestinal disorders, overactive bladder, urinary incontinence, poisoning, muscle spasms, motion sickness, chronic obstructive pulmonary disease (COPD), hyperhidrosis or any combination thereof. For example, the anticholinergics herein can be used to treat asthma, diarrhea, motion sickness, gastrointestinal disorders, overactive bladder, urinary incontinence, poisoning, muscle spasms, motion sickness, chronic obstructive pulmonary disease (COPD) or hyperhidrosis. In some embodiments, the compositions herein can be used to treat schizophrenia, psychosis, schizoaffective disorder, bipolar disorder, depression or any combination thereof. In some cases, anticholinergics such as thioridazine, haloperidol, olanzapine or any salt of these can be used to treat chemical sensory dysfunction. In some cases, chemical sensory dysfunction can include phantom olfaction (phantosmia) or taste hallucination (phantogeusia).
[0129] In some cases, the method herein can be used to treat chemical sensory dysfunction, such as loss of taste and / or loss of smell. In some cases, chemical sensory dysfunction can be caused at least in part by allergies, sinus infections, nasal polyps, inflammation, traumatic accidents, neurodegenerative disorders or idiopathic causes. In some cases, chemical sensory dysfunction can be caused at least in part by damage to the nervous system (e.g., sensory nervous system), or during or after damage to the nervous system (e.g., sensory nervous system). In some cases, chemical sensory dysfunction can be caused at least in part by coronavirus infection or its mutant form, or during or after coronavirus infection or its mutant form. In some cases, coronaviruses can include SARS-CoV-2 or its mutant form, which can cause disease COVID-19. In some cases, the method can include administering to the subject a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor described herein and / or a corticosteroid to treat chemical sensory dysfunction. In some cases, a PDE inhibitor can be administered in the form of an intranasal preparation, which is, for example, formulated as a spray containing droplets of a PDE inhibitor deposited into the nasal cavity. In some cases, the PDE inhibitor may be administered in a formulation in unit dosage form.
[0130] Chemical sensory disturbances may be associated with or related to a disease or condition such as sinusitis, nasal polyps, rhinitis, or any combination thereof. In some embodiments, chemical sensory disturbances may be associated with allergies such as allergic rhinitis. In some cases, allergies may include drug allergies, food allergies, insect allergies, latex allergies, mold allergies, pet allergies, pollen allergies, or a combination thereof.
[0131] In some cases, a method of treating a disease or condition in a subject in need thereof may include administering a corticosteroid, an ester thereof, or a salt thereof using a nasal spray device that delivers a dose unit in a plume upon actuation. In some cases, the dose unit may comprise a therapeutically effective amount of a corticosteroid, an ester thereof, or a salt thereof in a pharmaceutically acceptable carrier, diluent, excipient, or any combination thereof. In some cases, the plume may have a droplet size distribution characterized by: (a) less than about 1.5% of the droplets in the plume have a size less than about 10 μm; and (b) a D of about 38 μm to about 49 μm. 90 .
[0132] In some cases, a method of treating allergic rhinitis in a subject in need thereof may include administering to the subject an effective amount of a pharmaceutical composition comprising: a corticosteroid, an ester thereof, or a salt thereof and a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof. In some cases, the pharmaceutical composition forms a plume comprising more than one droplet after intranasal administration to the subject by actuating a nasal spray device comprising the liquid pharmaceutical composition, wherein the more than one droplet passes through a D 90 is characterized by a plume in which about 90% of the droplets have a diameter less than D 90 size.
[0133] In some cases, the method or composition of the present disclosure as described herein can be used to treat a subject suffering from a chemosensory disorder.Chemosensory disorders can include loss of smell (anosmia) or reduced ability to smell (hyposmia).Chemosensory disorders can include loss of taste (anosmia) or reduced ability to taste (hyposmia), such as reduced ability to taste sweet substances, sour substances, bitter substances or salty substances.In some cases, chemosensory disorders relate to misread or distorted smells or flavors or flavors.For example, chemosensory disorders can cause people to detect unpleasant smells or flavors from something that usually tastes or smells pleasant.In some cases, chemosensory dysfunction can include at least in part: loss of taste, loss of smell or both.Chemosensory dysfunction can include taste or olfactory disorders.In some cases, taste or olfactory disorders can include anosmia, hyposmia, anosmia, hyposmia, olfactory disorders (normal olfactory distortion), phantom olfaction, taste disorders (normal taste distortion), olfactory perversion or its combination.
[0134] In some cases, a corticosteroid, an ester thereof, or a salt thereof as described herein can be administered to a subject with a comorbidity. Such comorbidities can include, for example, hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infarction, stable angina, unstable angina, and Prinzmetal's angina, atherosclerosis, cardiogenic edema, heart disease, renal insufficiency, renal edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia (including Alzheimer's disease), immunodeficiency, premature labor, multiple sclerosis, dysmenorrhea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, vascular Conditions of reduced patency such as post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, respiratory disease, bronchitis, emphysema, lung cancer, cystic fibrosis, pneumonia, pleural effusion, allergic rhinitis, glaucoma, malignancy, and diseases characterized by disturbed bowel motility such as irritable bowel syndrome (IBS), rheumatoid arthritis, bacterial infections, fungal infections, parasitic infections, viral infections, HIV, systemic lupus erythematosus, psoriasis, other autoimmune diseases, Huntington's disease, and amyotrophic lateral sclerosis (ALS), or any combination thereof.
[0135] Administration and dosing
[0136] Disclosed herein are methods of treating a condition (e.g., allergic rhinitis, nasal polyps, or sinusitis) by administering a corticosteroid, an ester thereof, or a salt thereof as described herein. In some cases, administration may include administering a corticosteroid, an ester thereof, or a salt thereof in unit dosage form, such as in the form of a nasal spray. In some embodiments, the method of treatment may include nasal administration via a nasal spray device. Other methods of treatment include, by way of example only, oral administration, transmucosal administration, buccal administration, nasal administration, inhalation, parenteral administration, intravenous administration, subcutaneous administration, intramuscular administration, sublingual administration, transdermal administration, and rectal administration.
[0137] In some cases, application may include application to the nasal cavity. In some embodiments, application in the nasal cavity may include application to the nasal septum, nasal floor, nasal sidewall, inferior nasal meatus, middle nasal meatus, superior nasal meatus, olfactory cleft, olfactory region, nasal concha or any combination thereof. The nasal cavity is a space extending from the nostril to the nasopharynx. The inner boundary is the nasal septum, and the lower boundary is the nasal floor. The outer boundary includes the nasal sidewall including the nasal concha. The space between the nasal concha and the nasal sidewall (including the inferior nasal meatus, the middle nasal meatus, the superior nasal meatus and the sphenoethmoid recess) is in the nasal cavity. The upper boundary is defined by the skull base formed by the frontal bone, the ethmoid plate and the sphenoid bone. The olfactory nerve can be found in the upper part (superior aspect) of the nasal cavity in the olfactory region / olfactory cleft below the cribriform plate. In some embodiments, the nasal cavity may include the upper nasal cavity, the olfactory cleft, the olfactory epithelium or any combination thereof. In some cases, the nasal cavity may include squamous mucosa, olfactory mucosa, respiratory mucosa or a combination thereof. Application of the composition described herein may include application to any region of the nasal cavity. In some embodiments, the composition can be applied as a spray to at least partially cover the nasal cavity. In some cases, administration can include intranasal administration in one or both nostrils.
[0138] In some embodiments, the nasal spray plume can cover about 5% to about 99% of the surface area of the nasal cavity after actuation. In some embodiments, the nasal spray plume can cover about 10% to about 70% of the surface area of the nasal cavity after actuation. In some embodiments, the nasal spray plume can cover about 15% to about 50% of the surface area of the nasal cavity after actuation. In some embodiments, the nasal spray plume can cover more than about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the surface area of the nasal cavity after actuation. In some embodiments, the nasal spray plume, upon actuation, can cover about: 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0139] In some cases, administering can include administering to a sinus cavity. In some cases, administering can include administering to an ear, an eye, a mouth, or a combination thereof. In some cases, a sinus cavity can include an ethmoid sinus cavity, a maxillary sinus cavity, a frontal sinus cavity, or a sphenoid sinus cavity. In some cases, administering into a sinus cavity can include administering to a sinus ostium.
[0140] In some embodiments, a representative daily intranasal, lingual, pulmonary, topical or mucosal dose can be from about 1.0 μg / day to 2000 mg / day, from about 1.0 μg / day to 500.0 mg / day, from about 100 mg / day to 500 mg / day, from about 10 mg / day to 100.0 mg / day, from about 50 mg / day to 100.0 mg / day, from about 10 μg / day to 100.0 mg / day, from about 10 μg / day to about 10 mg / day, from about 100 mg / day to about 10 .... 1.0 mg / day, from about 10 μg / day to 500 μg / day, from about 20 μg / day to about 2000 μg / day, from about 100 μg / day to about 10,000 μg / day, from about 20 μg / day to about 200 μg / day, from about 10 μg / day to about 100 μg / day, from about 1 μg / day to 50 μg / day, or from about 10 μg / day to 30 μg / day of an active ingredient (e.g., a corticosteroid, an antihistamine, a decongestant, a vasoconstrictor, or any combination thereof). These dosage amount ranges represent the total dosage amount of the active ingredient per day for a given patient. In some embodiments, the dose administered daily may be less than about: 2000 mg / day, 1000 mg / day, 500 mg / day, 100 mg / day, 10 mg / day, 9 mg / day, 8 mg / day, 7 mg / day, 6 mg / day, 5 mg / day, 4 mg / day, 3 mg / day, 2 mg / day, 1 mg / day, 900 μg / day, 800 μg / day, 700 μg / day, 600 μg / day, 500 μg / day, 400 μg / day, 300 μg / day, 200 μg / day, 100 μg / day or 50 μg / day.In some embodiments, the daily dose may be at least about: 5 μg, 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg. g, 270μg, 280μg, 290μg, 300μg, 310μg, 320μg, 330μg, 340μg, 350μg, 360μg, 370μg, 380μg, 390μg, 400μg, 410μg, 420μg, 430μg, 440μg, 450μg, 460μg, 470μg, 480μg, 490μg, 500μg, 510μg, 520μg, 530μg, 540μg, 550 μg, 560μg, 570μg, 580μg, 590μg, 600μg, 610μg, 620μg, 630μg, 640μg, 650μg, 660μg, 670μg, 680μg, 690μg , 700μg, 710μg, 720μg, 730μg, 740μg, 750μg, 760μg, 770μg, 780μg, 790μg, 800μg, 810μg, 820μg, 830μg, 8 40μg, 850μg, 860μg, 870μg, 880μg, 890μg, 900μg, 910μg, 920μg, 930μg, 940μg, 950μg, 960μg, 970μg, 980 μg, 990 μg, 1000 μg, 1100 μg, 1200 μg, 1300 μg, 1400 μg, 1500 μg, 1600 μg, 1700 μg, 1800 μg, 1900 μg or about 2000 μg. In some embodiments, the daily dose administered can be at least about: 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg or 25 mg.
[0141] In some embodiments, representative dosage can be the actuation of each spray device per nostril, or multiple actuations of each spray device per nostril. In some embodiments, representative dosage can be the dosage for nostrils. In some embodiments, representative dosage can be from about 1.0 μg to 2000 mg, from about 1.0 μg to 500.0 mg, from about 100 mg to 500 mg / day, from about 10 mg to 100.0 mg / day, from about 50 mg to 100.0 mg / day, from about 10 μg to 100.0 mg, from about 10 μg to about 10 mg, from about 10 μg to 1.0 mg, from about 10 μg to 500 μg, from about 20 μg to about 2000 μg, from about 100 μg to about 10,000 μg, from about 1 μg to 50 μg / day or from about 10 μg to 30 μg / day of active ingredient (e.g., corticosteroid). In some embodiments, the dose administered may be less than about: 2000 mg, 1000 mg, 500 mg, 100 mg, 10 mg, 9 mg, 8 mg, 7 mg, 6 mg, 5 mg, 4 mg, 3 mg, 2 mg, 1 mg, 500 μg, 300 μg, 200 μg, 100 μg, or 50 μg of active ingredient.In some embodiments, the dose administered can be at least about or equal to: 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 210 μg, 220 μg, 230 μg, 240 μg, 250 μg, 260 μg, 270 μg, 0μg, 280μg, 290μg, 300μg, 310μg, 320μg, 330μg, 340μg, 350μg, 360μg, 370μg, 380μg, 390μg, 400μg, 410μ g, 420μg, 430μg, 440μg, 450μg, 460μg, 470μg, 480μg, 490μg, 500μg, 510μg, 520μg, 530μg, 540μg, 550μg, 5 60μg, 570μg, 580μg, 590μg, 600μg, 610μg, 620μg, 630μg, 640μg, 650μg, 660μg, 670μg, 680μg, 690μg, 700 μg, 710μg, 720μg, 730μg, 740μg, 750μg, 760μg, 770μg, 780μg, 790μg, 800μg, 810μg, 820μg, 830μg, 840μg, 850μg, 860μg, 870μg, 880μg, 890μg, 900μg, 910μg, 920μg, 930μg, 940μg, 950μg, 960μg, 970μg, 980μg, 990μg, 1000μg, 1100μg, 1200μg, 1300μg, 1400μg, 1500μg, 1600μg, 1700μg, 1800μg, 1900μg or about 2000μg of active ingredient. In some embodiments, the dose administered can be at least about: 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, or 25 mg of active ingredient.
[0142] In some embodiments, the therapeutically effective dose of an active ingredient delivered by an intranasal device herein may be about: 2, 3, 4, 5, 6, 7, 8, 9, or 10 times or more lower than the dose of the same active ingredient delivered by a standard intranasal spray device. For example, a nasal spray device herein may deliver an active ingredient such as a corticosteroid or an ester thereof at a dose of 20 μg and be as effective in treating a disease or condition as 50 μg of the same corticosteroid or an ester thereof delivered via a standard nasal spray device.
[0143] In some embodiments, on a per kilogram basis, a suitable dosage level of the compound can be from about 0.001 μg / kg body weight / day to about 10.0 mg / kg body weight / day, from about 0.5 μg / kg body weight / day to about 0.5 mg / kg body weight / day, from about 1.0 μg / kg body weight / day to about 100 μg / kg body weight / day, and from about 2.0 μg / kg body weight / day to about 50 μg / kg body weight / day. In some embodiments, a suitable dosage level of the active ingredient on a per kilogram basis can be less than about: 10.0 mg / kg body weight / day, 1 mg / kg body weight / day, 500 μg / kg body weight / day, 100 μg / kg body weight / day, 10 μg / kg body weight / day, or 1.0 μg / kg body weight / day of the compound. In some embodiments, suitable dosage levels on a per kilogram basis of the active ingredient may be at least about: 10.0 mg / kg body weight / day, 1 mg / kg body weight / day, 500 μg / kg body weight / day, 100 μg / kg body weight / day, 10 μg / kg body weight / day, or 1.0 μg / kg body weight / day of the active ingredient. In some embodiments, a suitable dosage level of the active ingredient on a per kilogram basis can be about: 0.5 μg / kg body weight, 1 μg / kg body weight, 1.5 μg / kg body weight, 2 μg / kg body weight, 2.5 μg / kg body weight, 3 μg / kg body weight, 3.5 μg / kg body weight, 4 μg / kg body weight, 4.5 μg / kg body weight, 5 μg / kg body weight, 5.5 μg / kg body weight, 6 μg / kg body weight, 6.5 μg / kg body weight, 7 μg / kg body weight, 7.5 μg / kg body weight, 8 μg / kg body weight, 8.5 μg / kg body weight, 9 μg / kg body weight, 9.5 μg / kg body weight, 10 μg / kg body weight, 10.5μg / kg body weight, 11μg / kg body weight, 11.5μg / kg body weight, 12μg / kg body weight, 12.5μg / kg body weight, 13μg / kg body weight, 13.5μg / kg body weight, 14μg / kg body weight, 14.5μg / kg body weight, 15μg / kg body weight, 15.5μg / kg body weight, 16μg / kg body weight, 16.5μg / kg body weight, 17μg / kg body weight, 17.5μg / kg body weight, 18μg / kg body weight, 18.5μg / kg body weight, 19μg / kg body weight, 19.5μg / kg body weight or 20μg / kg body weight.In some embodiments, a suitable dosage level on a per kilogram basis may be about: 100 μg / kg body weight, 150 μg / kg body weight, 200 μg / kg body weight, 250 μg / kg body weight, 300 μg / kg body weight, 350 μg / kg body weight, 400 μg / kg body weight, 450 μg / kg body weight, 500 μg / kg body weight, 550 μg / kg body weight, 600 μg / kg body weight, 650 μg / kg body weight, 700 μg / kg body weight, 750 μg / kg body weight, 800 μg / kg body weight, 850 μg / kg body weight, 900 μg / kg body weight, 950 μg / kg body weight, 1000 μg / kg body weight, 2 mg / kg body weight, 3 mg / kg body weight or 4 mg / kg body weight.
[0144] In some embodiments, one or more corticosteroids, its ester or its salt can be formulated in intranasal preparations such as intranasal spray preparations. In some embodiments, corticosteroids or its ester can include fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, any of these salts or any combination thereof. In some embodiments, intranasal preparations can include PDE inhibitors. In some embodiments, compounds described herein can be administered in the range of from about 0.0001 mg to about: 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg. In some cases, the dosage (e.g., dosage unit) of the compounds disclosed herein can be equal to or be at least about: 0.001 mg, 0.002 mg, 0.003 mg, 0.004 mg, 0.005 mg, 0.006 mg, 0.007 mg, 0.008 mg, 0.009 mg, 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg. In some embodiments, the formulation can be in unit dosage form. In some embodiments, the preparation may include a second active ingredient, such as a PDE inhibitor, or an antihistamine, or a vasoconstrictor, a decongestant, or any combination thereof. In some embodiments, the preparation does not include a second active ingredient. In some cases, the preparation may be a pharmaceutical composition, such as an intranasal preparation. In some cases, the composition may be a pharmaceutical composition.
[0145] In some cases, the amount applied can be the same as the amount applied to treat a particular disease, or can be an amount lower than the amount applied to treat the particular disease. The dose can be applied once a day or several times or multiple times a day. For example, a nasal spray can be applied once a day, twice a day, three times a day, or more than three times a day. In another example, a corticosteroid, an ester or a salt thereof, or any composition disclosed herein can be applied 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times a day. In some cases, a dose delivered to the nostrils by 1, 2, 3, 4, 5 or more actuations of a multi-dose nasal spray device can deliver a therapeutically effective amount of a composition disclosed herein. In some cases, the composition can be applied once, twice, or three times within a 24-hour period. In some cases, administration of a composition disclosed herein may be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times per week. In some cases, administration of a composition disclosed herein may be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 9, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more times. The dosage for treating a subject can produce the desired therapeutic effect or preventive effect without causing serious side effects.
[0146] Administration of the compositions disclosed herein can be carried out for a treatment duration of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days or more, consecutive or non-consecutive days. In some cases, the duration of treatment can be from about: 1 day to about 30 days, 1 day to about 60 days, 1 day to about 90 days, 30 days to about 90 days, 60 days to about 90 days, 30 days to about 180 days, from 90 days to about 180 days, or from 180 days to about 360 days.
[0147] The use of compositions disclosed herein can be continued for at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 1 year, at least about 2 years, at least about 3 years or continue the treatment duration of life. Can repeat in the life cycle of experimenter, such as once a month or once a year in the life cycle of experimenter. Use can be repeated in most of the time in experimenter's life, such as once a month or once a year and continue at least about 1 year, 5 years, 10 years, 15 years or longer.
[0148] In some cases, the composition can be administered in a single dose or in divided doses. In some cases, the composition described herein can be administered at a first time point and a second time point. In some cases, the composition can be administered so that the first administration can be administered before another administration, wherein the administration time difference is about: 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 4 days, 7 days, 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year or longer.
[0149] In some embodiments, administration can be continued for about: 1 day to about 8 days, 1 week to about 5 weeks, 1 month to about 12 months, 1 year to about 3 years, 3 years to about 10 years, 10 years to about 50 years, 25 years to about 100 years or 50 years to about 130 years. In some embodiments, the composition can be applied as needed, or the application continues: one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, one year or long-term administration. In some cases, administration can be intermittent administration. For example, the subject can apply the composition herein when needed, such as when they have allergies.
[0150] In some embodiments, administration of an effective amount of a corticosteroid, an ester thereof, or a salt thereof by intranasal (e.g., spray), lingual, pulmonary, topical, or mucosal administration does not produce a detectable blood level of a corticosteroid, an ester thereof, or a salt thereof. In some embodiments, administration of an effective amount of a corticosteroid, an ester thereof, or a salt thereof by intranasal, lingual, pulmonary, topical, or mucosal administration may produce a blood concentration of a corticosteroid, an ester thereof, or a salt thereof that is less than about: 5 mg / dl, 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl. In some embodiments, administration of an effective amount of a corticosteroid, an ester thereof, or a salt thereof by intranasal, lingual, pulmonary, topical, or mucosal administration can produce a blood concentration of the corticosteroid, an ester thereof, or a salt thereof that is greater than about: 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl. In some embodiments, administration of an effective amount of a corticosteroid, an ester thereof, or a salt thereof by intranasal, lingual, pulmonary, topical, or mucosal administration may produce a blood concentration of the corticosteroid, an ester thereof, or a salt thereof of about: 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl.
[0151] In some embodiments, administration of an effective amount of an antihistamine, decongestant, or vasoconstrictor by intranasal (e.g., spray), lingual, pulmonary, topical, or mucosal administration does not produce detectable blood levels of the antihistamine, decongestant, or vasoconstrictor. In some embodiments, administration of an effective amount of an antihistamine, decongestant, or vasoconstrictor by intranasal, lingual, pulmonary, topical, or mucosal administration may produce a blood concentration of the antihistamine, decongestant, or vasoconstrictor of less than about: 5 mg / dl, 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl. In some embodiments, administration of an effective amount of an antihistamine, decongestant, or vasoconstrictor by intranasal, lingual, pulmonary, topical, or mucosal administration may produce a blood concentration of the antihistamine, decongestant, or vasoconstrictor greater than about: 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl. In some embodiments, administration of an effective amount of an antihistamine, decongestant, or vasoconstrictor by intranasal, lingual, pulmonary, topical, or mucosal administration may produce a blood concentration of the antihistamine, decongestant, or vasoconstrictor of about: 2 mg / dl, 1 mg / dl, 500 μg / dl, 250 μg / dl, 100 μg / dl, 50 μg / dl, 25 μg / dl, 10 μg / dl, 5 μg / dl, or 1 μg / dl.
[0152] In some cases, the compositions described herein can be used together with one or more other therapeutic agents. In some cases, the compositions described herein can be used together with 2, 3, 4, 5, 6, 7, 8, 9 or 10 other therapeutic agents. For example, corticosteroids, their esters or their salts can be used together with the second therapy. In some cases, the second therapy can be used simultaneously or continuously. In some cases, other therapeutic agents can include antihistamines, decongestants, vasoconstrictors, immunotherapy, any of these salts or any combination thereof. In some cases, other therapeutic agents can include nonsteroidal anti-inflammatory drugs (NSAIDs). In some cases, other therapeutic agents can include anticholinergics.
[0153] In some cases, antihistamines may include nitrogen In some cases, the decongestant may include levomethamphetamine, naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, xylometazoline, any salt thereof or any combination thereof. In some cases, the vasoconstrictor may include amphetamine, antihistamine, caffeine, ergonovine, naphazoline, oxymetazoline, phenylephrine, propylhexedrine, pseudoephedrine, tetrahydrozoline, any salt thereof or any combination thereof. In some cases, other therapy may include mast cell stabilizers. In some cases, other therapy may include cromoglycine, such as sodium cromoglycate.
[0154] In some cases, NSAID can include salicylate, propionic acid derivatives, acetic acid derivatives, enolic acid derivatives, anthranilic acid derivatives, selective COX-2 inhibitors or sulfonanilides. In some cases, salicylate can include acetylsalicylic acid (aspirin), diflunisal (dolobid), salicylic acid, disalicylic acid, any of these salts or any combination thereof. In some cases, propionic acid derivatives can include ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, pebulubiprofen, zaltoprofen, any of these salts or any combination thereof. In some cases, acetic acid derivatives can include indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, bromfenac, nabumetone, any of these salts or any combination thereof. In some cases, enoic acid derivatives can include piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, phenylbutazone, any salt of these or any combination thereof. In some cases, anthranilic acid derivatives can include mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, any salt of these or any combination thereof. In some cases, selective COX-2 inhibitors can include celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib, any salt of these or any combination thereof. In some cases, sulfonanilides can include nimesulide or its salt. In some cases, NSAID can include clonixin, levofloxacin, harpagine, any salt of these or any combination thereof.
[0155] In some cases, the anticholinergic can include amitriptyline, atropine, aclidinium bromide, benztropine, chlorpheniramine, chlorpromazine, clomipramine, clozapine, cyclobenzaprine, cyproheptadine, darifenacin, desipramine, dexchlorpheniramine, dicyclomine, diphenhydramine, doxepin, hydroxyzine, scopolamine, imipramine, meclizine, nortriptyline, olanzapine, o-phenadrine, oxybutynin, paroxetine, perphenazine, prochlorperazine, promethazine, protriptyline, pseudoephedrine hcl / triprolidine hcl, scopolamine, thioridazine, tolterodine, trifluoperazine, trihexyphenidyl, trimipramine, a salt of any of these, or any combination thereof.
[0156] In some cases, the second therapy may include redecivir, its salt, chloroquine, its salt, lopinavir, its salt, ritonavir, its salt, monolavir, its salt, favipiravir, its salt, interferon beta, its salt, antiviral agent, oxygen or any combination thereof. In some cases, the second therapy may include peramivir, its salt, zanamivir, its salt, oseltamivir phosphate, oseltamivir, its salt, baloxavir marboxil, its salt or any combination thereof. In some cases, additional therapeutic agents may include nitric oxide, steroids, nonsteroidal anti-inflammatory drugs (NSAID) or any combination thereof. In some cases, additional therapy may be included in a nasal spray comprising a corticosteroid, its ester or its salt. In some cases, additional therapy may not be included in a nasal spray comprising a corticosteroid, its ester or its salt.
[0157] In some cases, additional therapy may include a PDE inhibitor or a salt thereof. In some cases, additional therapy may include 1, 2, 3, 4 or more PDE inhibitors or salts thereof. Examples of PDE inhibitors may include, for example, filminster, pyramide, rolipram, Org 20241, MCI-154, roflumilast, topolinone, posicar, lisazine, zaprinast, sildenafil, pyrazolopyrimidone, motapidone, pimobendan, zadaverine, cyanoguanazoldan, CI-930, EMD 53998, imazodine, saturinone, loprinone hydrochloride, 3-pyridinecarbonitrile derivatives, denbufyllene, abiphylline, tobaphylline, doxofylline, theophylline, pentoxofylline, nanlinone, cilostazol, cilostamide, MS 857, piloxetine, milrinone, amrinone, tolafenamide, dipyridamole, papaverine, E4021, thienopyrimidine derivatives, triflusal, ICOS-351, tetrahydropiperazine [1,2-b] β-carboline-1,4-dione derivatives, carboline derivatives, 2-pyrazolin-5-one derivatives, fused pyridazine derivatives, quinazoline derivatives, anthranilic acid derivatives, imidazoquinazoline derivatives, salts of any of these, and the like.
[0158] In some cases, additional therapies may include selective PDE inhibitors. The PDE inhibitor may be a selective PDE inhibitor or a nonspecific PDE inhibitor. The PDE selective inhibitor may include a PDE1 selective inhibitor, a PDE2 selective inhibitor, a PDE3 selective inhibitor, a PDE4 selective inhibitor, a PDE5 selective inhibitor, a PDE6 selective inhibitor, a PDE7 selective inhibitor, a PDE8 selective inhibitor, a PDE9 selective inhibitor, a PDE10 selective inhibitor, or a PDE11 selective inhibitor. In some cases, the selective PDE inhibitor may be specific to more than one of PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, and PDE11. Nonspecific PDE may include a PDE inhibitor that inhibits at least two, three, four, or five or more of PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, and PDE11.
[0159] In some cases, additional therapy may include non-selective PDE inhibitors. Non-specific PDE inhibitors may include theophylline, papaverine, caffeine, IBMX (3-isobutyl-1-methylxanthine, aminophylline, doxofylline, cipamphylline, theobromine, pentoxifylline (oxpentifylline), dyphylline or a salt of any of these. Theophylline is a methylxanthine derivative that can be used to treat chemosensory dysfunction when used as described herein. In some cases, anti-inflammatory effects may be achieved when theophylline is prescribed or administered so that the systemic level of theophylline in the blood is well below the level that causes side effects. When the symptoms of patients with emphysema and chronic bronchitis are partially related to reversible airway narrowing, theophylline may also be used to help patients with emphysema and chronic bronchitis.
[0160] PDE1 selective inhibitors, formerly known as calcium-dependent and calmodulin-dependent phosphodiesterases, can include ethyl 14-carboxylate (vinpocetine). In some cases, vinpocetine can be used to induce vasodilation on brain smooth muscle tissue. In some cases, PDE1 selective inhibitors can include IC86340, amiodarone, lisinopril, 8-methoxymethyl-IBMX, a salt of any of these, or any combination thereof. In some cases, PDE1 selective inhibitors can include vinpocetine or a salt thereof.
[0161] PDE2 selective inhibitors may include EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine), 9-(6-phenyl-2-oxohexan-3-yl)-2-(3,4-dimethoxybenzyl)-purin-6-one (PDP), BAY 60-7750, or a salt of any of these.
[0162] PDE3 selective inhibitors can include enoximone, milrinone (Primacor), amrinone, cilostazolamide, cilostazol (Pletal), troquinein or a salt of any of these. PDE3 inhibitors can produce sympathetic stimulation to increase cardiac inotropy, chronotropy and tropism when used as described herein. PDE3 inhibitors can also antagonize platelet aggregation, increase myocardial contractility, and enhance vascular and airway smooth muscle relaxation when used as described herein. PDE3A can be a regulator of the process. PDE3 inhibitors can effectively prevent aggregation when used as described herein. Cilostazol (Pletal) is approved for the treatment of intermittent claudication. Its mechanism of action may involve inhibition of platelet aggregation and inhibition of smooth muscle proliferation and vasodilation.
[0163] PDE4 selective inhibitors can include mesembryantrine, rolipram, ibudilast (i.e., neuroprotective and bronchodilatory drugs that can be used to treat asthma and stroke), and roflumilast (Daxas), cilomilast (Airflo) or a salt of any of these. In some cases, PDE4 selective inhibitors can be administered for the treatment of chronic obstructive pulmonary disease. PDE4 selective inhibitors can at least partially inhibit the release of inflammatory mediators such as cytokines or at least partially inhibit the generation of reactive oxygen species and immune cell infiltration. PDE4 inhibitors can also be used to treat asthma, arthritis and psoriasis.
[0164] PDE5 selective inhibitors may include sildenafil, tadalafil, vardenafil, udenafil, avanafil, and salts thereof.
[0165] Diagnosis and Measurement of Chemoreception Dysfunction
[0166] In some cases, the subject can be diagnosed (e.g., diagnosed with allergic rhinitis, nasal polyps, or sinusitis) prior to treatment with a corticosteroid, its ester, or its salt. In some cases, the method of treatment can include diagnosing allergic rhinitis, nasal polyps, or sinusitis in the subject. In some cases, the diagnosis can include in vitro assays. In some cases, the diagnosis can include physical assessments, skin prick tests, blood tests, patch tests, elimination diets, provocation tests, or allergy test kits. In some cases, the diagnosis can include visualizing the nasal cavity with an otoscope. In some cases, the diagnosis can include in vitro testing of nasal endoscopes, imaging studies (such as CT scans), and samples (such as nasal samples, sinus samples, or any combination thereof).
[0167] In some cases, treatment methods may include diagnosing chemical sensory dysfunction in a subject. In some cases, chemical sensory dysfunction may be related to allergic rhinitis, nasal polyps or sinusitis. In some cases, chemical sensory dysfunction can be diagnosed by detecting the sonic hedgehog factor at or below the threshold level in a biological sample from the human race. In some cases, chemical sensory dysfunction can be diagnosed by cyclic AMP (cAMP), cyclic GMP (cGMP), IL-10 or a combination thereof at, below or above the threshold level in a biological sample from the human race. In some cases, the sample may be a nasal sample or a saliva sample. In some cases, chemical sensory dysfunction can be diagnosed by detecting the cyclic nucleotide level at or below the threshold level in a biological sample from the human race. For example, low levels of cyclic nucleotides in a biological sample of a subject may prompt the subject to have chemical sensory dysfunction. Measurements for detecting the level of a biomaterial (e.g., cAMP) may be accomplished via ELISA, Western blot or any molecular biological assay. In some embodiments, chemical sensory dysfunction may be diagnosed by measuring a threshold, distinguishing, identifying or any combination of olfactory assays. In some cases, the diagnosis of chemical sensory dysfunction can include a detection recognition threshold (RT) score, an amplitude estimation (ME) score, a detection threshold (DT) score, a Hedonic (H) score, or a combination thereof, and comparison with a reference population (e.g., a population without chemical sensory dysfunction). The ME score refers to a measurement of a subject's ability to determine the intensity of a stimulus such as an odorant or taste agent. The RT score refers to a measurement of a subject's ability to identify the characteristics of a stimulus such as an odorant or taste agent. The DT score refers to a measurement of a subject's ability to identify exposure to a stimulus such as an odorant or taste agent as pleasant or unpleasant. The H score refers to a measurement of a subject's pleasant or unpleasant response to a stimulus such as an odorant or taste agent.
[0168] In some embodiments, the olfactometry of measuring threshold, discrimination, identification or any combination thereof can be applied to the subject. In some cases, the olfactometry can be applied before, during or after treatment. In some cases, the threshold determination can be used to determine the minimum concentration of the odorant that can be reliably detected. In some cases, the discrimination determination can be used to assess the ability of the subject to distinguish two or more different odors. In some cases, the identification determination can be used to assess the ability of the subject to identify a specific odor. In some cases, the olfactometry can be used to determine the efficacy of treatment. For example, the olfactometry can be completed before treatment and after treatment to determine the measurable changes of the sense of taste and / or loss of smell of the subject.
[0169] In some embodiments, the subject may experience a clinically detectable improvement in allergic rhinitis, nasal polyps, sinusitis, or any combination thereof within about 1 day to about 1 week, 1 week to about 6 weeks, 1 week to about 4 weeks, 2 weeks to about 5 weeks, or about 3 weeks to about 4 weeks of initiating treatment. In some embodiments, the subject may experience a clinically detectable improvement in taste or olfactory function within about 1 week to about 6 weeks, 1 week to about 4 weeks, 2 weeks to about 5 weeks, or about 3 weeks to about 4 weeks of initiating treatment. In some embodiments, the subject may experience a clinically detectable improvement in taste or olfactory function within about 1 month to about 6 months, 1 month to about 4 months, 2 months to about 5 months, or about 3 months to about 4 months of initiating treatment.
[0170] The known hedgehog signal transduction pathway is a key regulator of animal development, particularly during the late stages of embryogenesis and metamorphosis. Mammals have three members of the hedgehog signal transduction pathway, sonic hedgehog (SHH), desert hedgehog (DHH) and Indian hedgehog (IHH). This approach is relevant to the development of some cancers. The members of the hedgehog signal transduction pathway can be used for diagnosing and treating the loss and / or distortion of taste or smell, such as hyposmia, dysosmia, anosmia, phantom olfaction, hypogeusia, dysgeusia, taste hallucination and / or anosmia. For example, after treatment with a PDE inhibitor or corticosteroid, compared with its level before treatment, a subject with chemical sensory dysfunction can have an increased SHH level.
[0171] One or more members of the hedgehog signaling pathway may be selected from the group consisting of: sonic hedgehog (SHH), desert hedgehog (DHH) and / or Indian hedgehog (IHH). One or more members of the hedgehog signaling pathway may be SHH, DHH, IHH or any combination thereof. Although mammalian (e.g., human) hedgehog may be measured, it is also contemplated that non-mammalian hedgehog may be measured. In some cases, chemosensory dysfunction in a subject may be determined by detecting the levels of: sonic hedgehog (SHH), which may be in the range of from about greater than 0 pg / mL to about 8,500 pg / mL; the level of Indian hedgehog (IHH), which may be in the range of from about greater than 0 pg / mL to about 1.0 pg / mL; or the level of desert hedgehog (DHH), which may be in the range of from about greater than 0 pg / mL to about 5.0 pg / mL; or a combination thereof.
[0172] In patients who exhibit loss and / or distortion of taste or smell (e.g., hyposmia, dysosmia, anosmia, phantom smells, hypogeusia, dysgeusia, taste hallucinations, and / or anosmia), levels of hedgehog signaling pathway members may be lower than normal controls. For example, in patients with loss and / or distortion of taste or smell (e.g., chemosensory dysfunction), in some cases, the level of SHH can be about 0 pg / mL, greater than 0 pg / mL to less than 1 pg / mL, 1 pg / mL to 25 pg / mL, 15 pg / mL to 30 pg / mL, 20 pg / mL to 40 pg / mL, 35 pg / mL to 50 pg / mL, 45 pg / mL to 100 pg / mL, 75 pg / mL to 150 pg / mL, 125 pg / mL to 1000 pg / mL, 900 pg / mL to 2500 pg / mL, 2000 pg / mL to 5000 pg / mL, (b) the level of IHH can be about: 0 pg / mL, greater than 0 pg / mL to 0.1 pg / mL, 0.05 pg / mL to 0.15 pg / mL, 0.125 pg / mL to 0.2 pg / mL, 0.15 pg / mL to 0.30 pg / mL, 0.25 pg / mL to 0.5 pg / mL, 0.4 pg / mL to 0.7 pg / mL, 0.6 pg / mL to 0.75 pg / mL, 0.725 pg / mL to 0.9 pg / mL, 0.8 pg / mL to 0.9 pg / mL, 0.10 ... g / mL to 1.0pg / mL, less than 1.0pg / mL, less than 0.05ng / mL, less than 0.15ng / mL, less than 0.2ng / mL, less than 0.3ng / mL, less than 0.5ng / mL, less than 0.7ng / mL, less than 0.75ng / mL, less than 0.9ng / mL, less than 1.0ng / mL, less than 1.1ng / mL, less than 1.5ng / mL, less than 1.75ng / mL, less than 2.0ng / mL, less than 2.25ng / mL, less than 5.0ng / mL, less than 6.0ng / mL, less than 7.0ng / mL, less than 10.0ng / mL , or less than 100.0 ng / mL; (c) the level of DHH can be about: 0 pg / mL, greater than 0 pg / mL to 0.1 pg / mL, 0.05 pg / mL to 0.15 pg / mL, 0.125 pg / mL to 0.2 pg / mL, 0.15 pg / mL to 0.30 pg / mL, 0.25 pg / mL to 0.5 pg / mL, 0.4 pg / mL to 0.7 pg / mL, 0.6 pg / mL to 0.75 pg / mL, 0.725 pg / mL to 0.9 pg / mL, 0.8 pg / mL to 1.0 pg / mL, 0.9 pg / mL to 1.1 pg / mL, 1.0pg / mL to 1.3pg / mL, 1.2pg / mL to 1.5pg / mL, 1.4pg / mL to 2.0pg / mL, 1.9pg / mL to 2.5pg / mL, 2.4pg / mL to 3.0pg / mL, 2.9pg / mL to 3.5pg / mL, 3.4pg / mL to 3.8pg / mL, 3.7pg / mL to 3.9pg / mL, 3.85pg / mL to 5.0pg / mL, less than 5.0pg / mL, less than 0.05ng / mL, less than 0.15ng / mL L, less than 0.2 ng / mL, less than 0.3 ng / mL, less than 0.5 ng / mL, less than 0.7 ng / mL, less than 0.75 ng / mL, less than 0.9 ng / mL, less than 1.0 ng / mL, less than 1.1 ng / mL, less than 1.5 ng / mL, less than 1.75 ng / mL, less than 2.0 ng / mL, less than 2.25 ng / mL, less than 5.0 ng / mL, less than 6.0 ng / mL, less than 7.0 ng / mL, less than 10.0 ng / mL, or less than 100.0 ng / mL. However, there can be some inter-patient variability as the levels of different members of the Hedgehog signaling pathway vary based on the individual. .
[0173] In some embodiments, administration of an effective amount of a PDE inhibitor or another compound disclosed herein, such as a corticosteroid, can increase salivary and / or nasal mucus SHH, DHH and / or IHH levels in a human by at least about: 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or about 50% relative to these levels in the human prior to administration of a therapeutically effective amount of a PDE inhibitor or corticosteroid. In some cases, an increase in salivary and / or nasal mucus SHH, DHH and / or IHH levels is observed after about 1 day to about 10 days, 30 days to about 90 days, 15 days to about 45 days, or 30 days of continuous treatment with a therapeutically effective amount of a PDE inhibitor or corticosteroid.
[0174] In some embodiments, administration of an effective amount of a PDE inhibitor or corticosteroid can increase or decrease a biological compound, such as a protein or metabolite. In some embodiments, administration of an effective amount of a PDE inhibitor or another compound disclosed herein can increase salivary and / or nasal mucus cAMP or cGMP levels in a human by at least about: 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or about 50% relative to such levels in a human prior to administration of a therapeutically effective amount of a PDE inhibitor or other compound. In some cases, increases in saliva and / or nasal mucus cAMP or cGMP levels are observed after about 1 day to about 10 days, 30 days to about 90 days, 15 days to about 45 days, or 30 days of continuous treatment with a therapeutically effective amount of a PDE inhibitor or another compound disclosed herein.
[0175] In some embodiments, administration of an effective amount of a PDE inhibitor or another compound disclosed herein (e.g., a corticosteroid) can reduce salivary and / or nasal mucus IL-10 levels in a human by at least about: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 5 %, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or about 50%. In some cases, a decrease in saliva and / or nasal mucus IL-10 levels is observed after about the following time: continuous treatment with a therapeutically effective amount of a PDE inhibitor or corticosteroid for 1 day to about 10 days, 30 days to about 90 days, 15 days to about 45 days, or 30 days. IL-10 levels can be measured using an enzyme-linked immunosorbent assay (ELISA), Western blot, or other protein measurement assay.
[0176] In some embodiments, the PDE inhibitor and / or corticosteroid in the form of liquid spray of effective dose can increase taste or olfactory acuity.In some embodiments, compared with untreated state, the increase of taste or olfactory acuity can be at least about: 5%, 10%, 20%, 30%, 40%, 50%, 75% or 100%.In some embodiments, taste or olfactory acuity can be increased to at least about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of normal individual acuity. In some cases, the increase in taste or smell acuity can be measured after about 10 days to about 20 days, 15 days to about 30 days, 25 days to about 50 days, 1 month to about 6 months, 4 months to 12 months, 6 months to 18 months, or 6 months to about 3 years. In some cases, the increase in taste or smell acuity can be measured after about 30 days. In some embodiments, the taste or smell acuity can be measured objectively. In some embodiments, the taste or smell acuity can be measured subjectively. In some cases, the olfactory acuity can be measured by detection threshold, recognition threshold, hedonic, amplitude estimation, or any method described herein.
[0177] Reagent test kit
[0178] For the purposes of the therapeutic composition described herein, kits and articles of manufacture are also described. In some embodiments, such kits include carriers, packaging or containers, which are separated to receive one or more blister packages, bottles, tubes, capsules and the like. In certain embodiments, the pharmaceutical composition is present in a package or dispenser device, which includes one or more unit dosage forms of compounds provided herein. In other embodiments, the package may include metal or plastic foil, such as a blister package. In some embodiments, the package includes a capsule, a vial or a tube. In other embodiments, the package or dispenser device is accompanied by instructions for use. In some embodiments, the dispenser is disposable or single use, and in other embodiments, the dispenser is reusable. In certain embodiments, the pharmaceutical preparation is preloaded into the device. In some embodiments, the kit may include a spray device as disclosed herein.
[0179] In other embodiments, the packaging may also be accompanied by a notice as required by a governmental agency that regulates the manufacture, use or sale of the drug. The notice indicates that the drug has been approved by a human or veterinary regulatory agency. For example, such a notice is a label or approved product insert for a prescription drug approved by the U.S. Food and Drug Administration. Compositions of compounds provided herein formulated in compatible excipients, diluents and / or carriers are also prepared, placed in a suitable container, and labeled for use in treating a specified condition.
[0180] Articles provided herein can also include an application device or a dispensing device. Examples of application devices include intranasal sprayers and inhalers. A pump and / or a spray head (e.g., a nozzle) can be provided with a sprayer and an intranasal device, or a pump and / or a spray head can be built into the device. Alternatively, a propellant can be included in the device or it can be stored in the device. In some cases, a propellant can be used together with a spray device disclosed herein.
[0181] Such a kit can include an identification description or label of a container. In other embodiments, the label is on a container with letters, numbers or other characters forming a label, and is attached, molded or etched into the container itself; when the label is present in a receiver (receptacle) or a carrier that also keeps the container, for example, as a package insert, the label is associated with the container. In some embodiments, the label is used to indicate that the content is to be used for a specific therapeutic application. In other embodiments, the label also indicates the instructions for use of the content, such as in the method described herein. In some embodiments, a group of instructions can also be included, usually in the form of a package insert. The information material can include instructions about how to distribute the pharmaceutical composition, including the type of the patient that can be treated, timetable (such as dosage and frequency) and similar descriptions.
[0182] The present disclosure also relates to kits (kits) consisting of individual packages of the kit, which are often assembled for shipping or for patient convenience, such as a weekly, biweekly or monthly supply of medication. Example
[0183] Example 1: Dispensing of liquid formulations in a nasal model by different nasal spray devices
[0184] The ability of three types of nasal spray devices to deposit liquid formulations in a nasal model was tested. 1 mg / mL calcein (for fluorescence visualization) was added to a formulation containing theophylline (600 μg / mL) without a viscosity enhancer. In addition, 1 mg / mL calcein was added to a separate formulation containing theophylline (600 μg / mL) and a viscosity enhancer (carboxymethylcellulose). The formulation also contained citric acid and sodium hydroxide as buffers, and phenylethanol as a preservative. Purified water was the carrier. The test was conducted at 60% relative humidity. The formulations were tested in three different nasal spray devices: soft mist nasal spray, slow standard nasal spray, and standard nasal spray. Figure 1 The images in show two actuations of the spray device tested per image (90 μl of liquid spray). Table 1 shows the nasal coverage of the different spray devices in the nasal model. In the nasal model, the soft mist nasal spray without viscosity enhancer had the greatest surface coverage (about 40%). The soft mist nasal spray targeted the olfactory area and nasal concha. The addition of cellulose reduced the surface area covered to approximately 20% of the nasal mucosa. However, the spray was more concentrated in the olfactory area, as shown in Figure 1. Figure 1 Shown and indicated by an ellipse. Furthermore, the focus of the soft mist nasal spray on the olfactory region compared to the standard nasal spray was surprising and unexpected, as this region is known to influence chemosensory function.
[0185] Table 1 Surface coverage of nasal spray
[0186]
[0187]
[0188] Example 2: Nasal spray characteristics of three nasal spray devices
[0189] Theophylline liquid formulation was actuated using three spray devices: a soft mist nasal spray device, a slow standard nasal spray device, and a standard nasal spray device. Actuation data are available at Figure 2 As shown in the figure. The left Y-axis shows the cumulative volume (%) of each spray and is shown by the S-shaped line. The X-axis shows the particle size of the droplets (μm). The right Y-axis shows the volume frequency (%) of the droplet size. About 50% of the droplets of the soft mist nasal spray have a particle size less than 20μm and there are generally no particles over 60μm in size. About 50% of the droplets of the slow standard nasal spray have a particle size less than 30μm, and the remaining 50% of the particles are about 30μm to about 100μm in size. About 50% of the droplets of the standard nasal spray have a particle size less than about 60μm, and the remaining particles are about 60μm to about 200μm in size. As shown in the figure. Figure 1 and Figure 2 As shown, the small droplet size of the soft mist nasal spray concentrates the formulation to the olfactory area.
[0190] Example 3: Treatment of allergic rhinitis in a subject
[0191] The subject was admitted to a clinic with nasal congestion, sneezing, itchy and watery eyes. The subject was diagnosed with allergic rhinitis. The subject was prescribed a fluticasone propionate composition in a nasal spray device as described herein. The subject applied the nasal spray in each nostril at an effective dose once daily. The nasal spray was administered by a nasal spray comprising about 15 μm to about 24 μm D 50 , D from about 30 μm to about 50 μm 90 The subject has reduced symptoms of allergic rhinitis (e.g., reduced sneezing, itchy eyes, nasal congestion, and watery eyes) after administration of fluticasone propionate.
[0192] Example 4: Treatment of nasal polyps in a subject
[0193] The subject was admitted to a clinic due to abnormal growths in the subject's nasal passages. The subject was diagnosed with noncancerous nasal polyps. The subject was prescribed a budesonide composition in a nasal spray device as described herein. The subject applied the nasal spray twice daily in each nostril. The nasal spray was administered by a nasal spray comprising about 15 μm to about 24 μm of D 50 , D from about 30 μm to about 50 μm 90 The subject has a reduction in the size of nasal polyps after administration of budesonide.
[0194] Example 5: Treatment of Sinusitis in a Subject
[0195] The subject was admitted to the clinic with nasal congestion, nasal inflammation, facial pain (e.g., pain around the eyes, cheeks, nose, and forehead). The subject was diagnosed with a sinus infection. The subject was prescribed a beclomethasone dipropionate composition in a nasal spray device as described herein. The subject applied the nasal spray twice daily in each nostril. The nasal spray was administered by a nasal spray comprising about 15 μm to about 24 μm D 50 , D from about 30 μm to about 50 μm 90 The subject has reduced symptoms of sinus infection (e.g., reduced pain and nasal inflammation and congestion) after administration of beclomethasone dipropionate.
[0196] Example 6: Theophylline spray preparation
[0197] Table 2 shows two exemplary formulations of theophylline for nasal administration.
[0198] Table 2 - Theophylline Preparations
[0199]
[0200] Example 7: Soft Mist Nasal Spray Properties
[0201] The soft mist nasal spray devices were tested to determine the spray characteristics of the soft mist nasal spray after actuation. An automated system was used to test 3 or 6 devices. The actuation stroke lengths of the nasal spray devices were 4.6 mm, 4.8 mm, and 4.9 mm. The actuator stroke (AS) acceleration was approximately 500 mm / sec 2 (mm / s 2 ), the AS speed was 1 mm / sec, 2 mm / sec, 3 mm / sec or 4 mm / sec (mm / s). The average holding time (i.e., the average amount of time the spray device was pressed) was 684 milliseconds (ms). For each device, each experiment was tested with 3 or 6 dosing shots per AS speed. Prior to testing, the device was activated with several actuations. The composition was tested in a formulation comprising 2.8 mg / ml theophylline, preservatives (benzalkonium chloride and phenylethyl alcohol) and saline. The spray device had 48 nozzle holes with a size of 4 μm per nozzle hole and a cone angle of 20 °. Figure 3-Figure 6 and Figure 8-Figure 13 The box and whisker plot of is described below. The box is the range from the 25th to the 75th percentile. The line in the box is the median (50th percentile). The whiskers are the maximum and minimum values—unless they are considered outliers, which are shown as circles. No whiskers means the lower quartile value is equal to the minimum value, and the upper quartile value is equal to the maximum value.
[0202] The measured emission weight (amount released in mg) is Figure 3 Shown in. Figure 3 A box-and-whisker plot is depicted showing the metered shot weight (amount released in milligrams (mg)) from a soft mist pump device on the Y-axis at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s, and 4 mm / s (mm / s)) on the upper X-axis and 4.6 mm, 4.8 mm, and 4.9 mm stroke lengths shown on the lower X-axis. The actuation speeds of 2 mm / s and 3 mm / s are within about 20% of the target shot weight of 45 mg.
[0203] The delivered emission weight (amount delivered in mg) is Figure 4 Shown in. Figure 4A box-and-whisker plot is depicted showing the delivered shot weight (amount delivered in milligrams (mg)) from a soft mist pump device on the Y-axis at different actuation speeds (1 mm / s, 2 mm / s, 3 mm / s, and 4 mm / s (mm / s)) on the upper X-axis and 4.6 mm, 4.8 mm, and 4.9 mm stroke lengths shown on the lower X-axis. The actuation speeds of 1 mm / s, 2 mm / s, and 3 mm / s were within approximately 20% of the target shot weight of 45 mg.
[0204] The spray plume geometry at a pattern distance of 60 mm is Figure 5 Shown in. Figure 5 A box-and-whisker plot is depicted showing the plume geometry performance (plume angle (degrees) and plume width (mm)) from a soft mist pump device on the Y-axis at different actuation speeds (1 millimeter / second, 2 millimeter / second, 3 millimeter / second (mm / s)) on the X-axis at a stroke length of 4.8 mm. The plume angle is about 15 degrees to about 40 degrees. The plume width is about 15 mm to about 45 mm. Several spray patterns could not be determined, such as 1 repeat for 1 mm / second for device #11 and 2 repeats for 1 mm / second for device #13.
[0205] The spray pattern performance at 30mm and 60mm is Figure 6 Shown in. Figure 6 Depicted are box-and-whisker plots showing Dmax (mm), Dmin (mm), ellipticity and area (mm) on the Y-axis at different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis at 4.8 mm stroke length, at 30 mm and 60 mm pattern distances shown on the upper X-axis. 2 ) of the spray pattern. For a spray distance of 30 mm, Dmax (maximum diameter) is 15-20 mm, Dmin (minimum diameter) is about 14 mm, the ellipticity is about 1.1-1.3, and the area is about 180-200 mm 2 For a spray distance at 60 mm, Dmax (maximum diameter) is about 30-50 mm, Dmin (minimum diameter) is about 20-30 mm, ellipticity is about 1.1-1.8, and area is about 600-1000 mm 2 At 60 mm, repeating device #13 at 2 mm / sec did not produce a quantifiable pattern.
[0206] The spray pattern at 30mm and 60mm pattern distance is Figure 7 Shown in. Figure 7Depicted are images showing the following: spray patterns at 30 mm and 60 mm pattern distances from a soft mist pump device (device 12) at different actuation speeds (2 mm / s and 3 mm / s (mm / s)) and at a 4.8 mm stroke length. In some cases, the spray pattern parameters at 60 mm could not be calculated due to the dispersion of the spray produced at 60 mm. Images were captured by a non-impact laser method on a Proveris Sprayview device. In a non-impact laser method, a laser sheet is projected and an image of the droplet concentration across the laser plane is produced.
[0207] The droplet size distribution at 30 mm and 60 mm pattern distance is Figure 8 Shown in. Figure 8 Depicted are box-and-whisker plots showing droplet size distribution (volume % <10 μm; span; D) on the Y-axis for different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis at 30 mm and 60 mm pattern distances shown on the upper X-axis for a stroke length of 4.8 mm. 90 value (μm); and D 50 For the spray device at 30 mm, the volume % <10 μm is about 0.25% to about 2%, the span is about 0.8 to about 1.6, D 90 The value is about 30-55 μm; and D 50 The value is about 21-28 μm. For the spray device at 60 mm, the volume % <10 μm is less than about 1%, and the span is about 0.8 to about 1.2, D 90 The value is about 40-50 μm; and D 50 The value is about 26-30μm.
[0208] The plume geometry at a pattern distance of 60 mm is Fig. 9 Shown in. Fig. 9 A box-and-whisker plot is depicted showing the plume geometry performance (plume angle (degrees) and plume width (mm)) on the Y-axis for different actuation speeds (1 millimeter / second, 2 millimeter / second, 3 millimeter / second (mm / s)) on the lower X-axis for 4.6 mm and 4.8 mm stroke lengths on the upper X-axis. At a stroke length of 4.6 mm, the plume angle was about 25-40 degrees and the plume width was about 25-40 mm. At a stroke length of 4.8 mm, the plume angle was about 15-40 degrees and the plume width was about 15-40 mm. In some cases, no spray was detected at a speed of 1 mm / second.
[0209] The spray pattern performance at a pattern distance of 30 mm is Fig.10 Shown in. Fig.10Depicted are box-and-whisker plots showing the spray pattern (Dmax (mm), Dmin (mm), ellipticity and area (mm) on the Y-axis for different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis for 4.6 mm and 4.8 mm stroke lengths on the upper X-axis. 2 )). At a stroke length of 4.6 mm, Dmax is about 16-20 mm, Dmin is about 13-14.5 mm, ellipticity is about 1.1-1.4 and area is about 170-210 mm 2 At a stroke length of 4.8 mm, Dmax is about 16-20 mm, Dmin is about 13.5-14.75 mm, ellipticity is about 1.1-1.3 and area is about 170-210 mm 2 .
[0210] The spray pattern performance at a pattern distance of 60 mm is Fig.11 Shown in. Fig.11 Depicted are box-and-whisker plots showing the spray pattern (Dmax (mm), Dmin (mm), ellipticity and area (mm) on the Y-axis for different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis for 4.6 mm and 4.8 mm stroke lengths on the upper X-axis. 2 )). At a stroke length of 4.6 mm, Dmax is about 30-45 mm, Dmin is about 21-32 mm, ellipticity is about 1.1-1.6, and area is about 500-1200 mm 2 At a stroke length of 4.8 mm, Dmax is about 30-50 mm, Dmin is about 24-32 mm, ellipticity is about 1.1-1.8, and area is about 600-1000 mm 2 In some cases, the spray pattern parameters at 60 mm could not be calculated due to the dispersion of the spray at a distance of 60 mm.
[0211] The droplet size distribution at a spray distance of 30 mm is Fig.12 Shown in. Fig.12 Depicted are box-and-whisker plots showing the droplet size distribution (volume % <10 μm; span; D) on the Y-axis for stroke lengths of 4.6 mm and 4.8 mm on the upper X-axis and different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis. 90 value (μm); and D 50 Value (μm). At 4.6 mm stroke length, the volume % <10 μm is about 0.5%-2%, the span is about 0.8 to about 1.6, D 90 The value is about 35-52 μm; and D 50The value is about 21-26 μm. At 4.8 mm stroke length, the volume % <10 μm is about 0.25%-1.75%, spanning from about 0.8 to about 1.6, D 90 The value is about 30-55 μm; and D 50 The value is about 21-27 μm.
[0212] The droplet size distribution at a spray distance of 60 mm is Fig.13 Shown in. Fig.13 Depicted are box-and-whisker plots showing the droplet size distribution (volume % <10 μm; span; D) on the Y-axis for stroke lengths of 4.6 mm and 4.8 mm on the upper X-axis and different actuation speeds (2 mm / s and 3 mm / s) on the lower X-axis. 90 value (μm); and D 50 Value (μm). At 4.6 mm stroke length, the volume % <10 μm is less than 2.5%, spanning from about 0.8 to about 1.4, D 90 The value is about 36-63 μm; and D 50 The value is about 23-34 μm. At a stroke length of 4.8 mm, the volume % <10 μm is less than about 1%, and the span is about 0.8 to about 1.1, D 90 The value is about 40-50 μm; and D 50 The value is about 25-30 μm.
[0213] A summary of the droplet size distribution is presented in Table 3. Table 3 shows the droplet size distribution according to: pattern distance or tip distance (30 mm or 60 mm); actuator stroke speed (2 mm / s and 3 mm / s); and stroke length (4.6 mm and 4.8 mm). D 10 Value (μm), D 50 Value (μm), D 90 The mean, standard deviation and coefficient of variation (CV) of the values (μm), volume percentage <10 μm, volume percentage <5 μm and span were calculated.
[0214] Table 3: Summary of droplet size distribution by soft mist spray device
[0215]
[0216]
[0217] Example 8: Non-aqueous nasal preparation of theophylline
[0218] Two non-aqueous theophylline formulations were developed and are shown in Tables 4 and 5. In some cases, the drug concentration (e.g., PDE inhibitor) in the formulation can be as high as 12 mg / mL. The formulation can be used with the nasal spray device described herein.
[0219] Table 4: Formulation A: 5.7 mg / mL theophylline
[0220] Element Function gram Theophylline Active ingredients 0.57 DMSO Solvent / vehicle 5 Oleyl alcohol Solvents, penetration enhancers 5 DEGEE(Transcutol P) Solvents, penetration enhancers 25 Dipropylene glycol Solvents, penetration enhancers 5 PEG 400 Solvent / vehicle 10 Propylene glycol Solvents, Penetration Enhancers 50 Hydroxypropyl Cellulose Solution thickener 0.04 total 100.61
[0221] Table 5: Formulation B: 11 mg / mL theophylline
[0222] Element gram Theophylline 1.11 DMSO 5 Oleyl alcohol 5 DEGEE(Transcutol P) 25 Dipropylene glycol 5 PEG 400 10 Propylene glycol 50 Hydroxypropyl Cellulose 0.4 total 101.51
[0223] Although preferred embodiments of the present disclosure have been shown and described herein, such embodiments are provided by way of example only. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed in practicing the present disclosure.
Claims
1. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) a corticosteroid, an ester or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof, wherein the liquid drug composition, upon intranasal administration to the subject by actuating a nasal spray device containing the liquid drug composition, forms a plume comprising more than one droplet, the more than one droplet passing through a D 90 wherein about 90% of the droplets in the plume have a diameter less than D 90 size, and wherein an effective amount of the pharmaceutical composition is administered to treat the disease or condition.
2. The method of claim 1, wherein the more than one droplet is further characterized by less than about 1.5% of the droplets in the plume having a size less than about 10 μm.
3. The method according to claim 1 or 2, wherein the more than one droplet also passes through a D of about 23 μm to about 30 μm. 50 wherein about 50% of the droplets in the plume have a D 50 size.
4. The method according to any one of claims 1 to 3, wherein the D 50 It is about 25μm.
5. The method according to any one of claims 1 to 4, wherein the droplet size is measured by laser diffraction.
6. The method of any one of claims 1-5, wherein the corticosteroid, its ester, or its salt comprises fluticasone, desonide, mometasone, beclomethasone, ciclesonide, triamcinolone acetonide, budesonide, flunisolide, its ester, its salt, or any combination thereof.
7. The method of claim 6 comprising the corticosteroid, ester or salt thereof comprising fluticasone or a salt thereof.
8. The method of any one of claims 1-7, wherein the plume is formed by actuation of the nasal spray device and lasts from about 0.5 seconds to about 5 seconds from the start of spraying to the end of spraying.
9. The method of any one of claims 1-8, wherein the pharmaceutically acceptable carrier comprises water.
10. The method of any one of claims 1-9, wherein the liquid pharmaceutical composition further comprises a viscosity enhancing agent.
11. The method according to any one of claims 1-10, wherein the liquid pharmaceutical composition further comprises an excipient.
12. The method according to any one of claims 1-11, wherein the liquid pharmaceutical composition further comprises a preservative.
13. The method of claim 8, wherein the actuation comprises an actuation volume of liquid of about 10 μl to about 200 μl, or about 20 μl to about 80 μl.
14. The method of any one of claims 1-13, wherein intranasal administration is once per day, twice per day, three times per day, or four times per day to each nostril.
15. The method of any one of claims 1-14, wherein the plume covers about 15% to about 50%, about 10% to about 80%, about 5% to about 90%, about 5% to about 100% of the surface area of the nasal cavity as measured by a nasal cast scan.
16. The method of claim 15, wherein the nasal cavity comprises a nasal septum, a nasal floor, a nasal lateral wall, an inferior nasal meatus, a middle nasal meatus, a superior nasal meatus, an olfactory cleft, an olfactory region, a turbinates, or any combination thereof.
17. The method of claim 15, wherein the nasal cavity comprises a nasal septum, a nasal floor, nasal lateral walls, an inferior meatus, a middle meatus, a superior meatus, an olfactory cleft, an olfactory region, and turbinates.
18. The method of any one of claims 1-17, wherein the liquid pharmaceutical composition is in a unit dose and comprises from about 10 μg to about 2000 μg of the corticosteroid, its ester, or its salt.
19. The method of any one of claims 1-18, wherein the disease or condition comprises allergic rhinitis, nasal polyps, sinusitis, or any combination thereof.
20. The method of any one of claims 1-18, wherein the disease or condition comprises symptoms of the disease or condition, and wherein the symptoms of the disease or condition comprise nasal congestion, sneezing, runny nose, itchy eyes, itchy nose, itchy throat, postnasal drip, fatigue, coughing, tearing, loss of smell, sore throat, snoring, headache, facial pain, purulent nasal drainage, fungal debris, foul odor, or any combination thereof.
21. The method of any one of claims 1-20, further comprising administering a second therapeutic agent.
22. The method of claim 21, wherein the liquid pharmaceutical composition further comprises the second therapeutic agent.
23. The method of claim 21, wherein the second therapeutic agent is administered simultaneously or consecutively with the administration.
24. The method of claim 21, wherein the second therapeutic agent comprises a PDE inhibitor, an antihistamine, a vasoconstrictor, a decongestant, or a salt of any of these.
25. The method of claim 21, wherein the second therapeutic agent comprises sodium cromolyn.
26. The method of claim 19, further comprising diagnosing the subject with the allergic rhinitis, the nasal polyps, the sinusitis, or any combination thereof.
27. The method of claim 1, wherein the nasal spray device delivers a plume as a unit dose upon actuation.
28. The method of claim 1, wherein the nasal spray device contains about 60 to about 120 unit doses, and wherein each unit dose contains about 10 μg to about 2000 μg of the corticosteroid, ester thereof, or salt thereof.
29. The method according to any one of claims 1-28, wherein the subject is a subject in need thereof.
30. The method of any one of claims 1-29, wherein the subject is a human.
31. The method of any one of claims 1-30, wherein upon actuation, the nasal spray device delivers about 35 mg to about 50 mg of the pharmaceutical composition.
32. The method of any one of claims 1-31, wherein the more than one droplet also passes through a D 10 wherein about 10% of the droplets in the plume have a D 10 size.
33. The method of any one of claims 1-32, wherein the nasal spray device has an actuated stroke length of 4.6 mm, 4.8 mm, or 4.9 mm.
34. The method of any one of claims 1-33, wherein the nasal spray device is actuated with an actuator stroke speed of 2 mm / s or 3 mm / s.
35. The method of any one of claims 1-34, wherein the nasal spray device is actuated at an actuator stroke acceleration of about 500 mm / s 2 .
36. The method of any one of claims 1-35, wherein the nasal spray device has a nozzle aperture of about 3 μm, about 4 μm, or about 5 μm.
37. The method of any one of claims 1-36, wherein the nasal spray device has about 40 to about 70 nozzle holes or about 45 nozzle holes to about 65 nozzle holes.
38. The method of any one of claims 1-37, wherein the nasal spray device has a cone angle of about 20 degrees.
39. A nasal spray device comprising: a corticosteroid, an ester thereof, or a salt thereof, wherein the nasal spray device is configured to deliver a dose unit in a plume upon actuation, wherein the dose unit comprises a therapeutically effective amount of the corticosteroid, an ester thereof, or a salt thereof in a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof, wherein the plume has a droplet size distribution characterized by: (a) less than about 1.5% of said droplets in said plume have a size less than about 10 μm; and (b) D from about 38 μm to about 49 μm 90 , wherein about 90% of the droplets in the plume have a diameter less than D 90 size.
40. A kit comprising the nasal spray device of claim 39 and a container.
41. A method of treating allergic rhinitis in a subject in need thereof, the method comprising administering a corticosteroid, an ester thereof, or a salt thereof using a nasal spray device that, upon actuation, delivers a dose unit in a plume, the dose unit comprising a therapeutically effective amount of the corticosteroid, an ester thereof, or a salt thereof in a liquid pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, excipient, or any combination thereof, wherein the plume comprises droplets and has a droplet size distribution characterized by: (a) less than about 1.5% of said droplets in said plume have a size less than about 10 μm; and (b) D from about 38 μm to about 49 μm 90 , wherein about 90% of the droplets in the plume have a diameter less than D 90 size.
42. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) an antihistamine or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof, wherein the liquid drug composition, upon intranasal administration to the subject by actuating a nasal spray device containing the liquid drug composition, forms a plume comprising more than one droplet, the more than one droplet passing through a D 90 wherein about 90% of the droplets in the plume have a diameter less than D 90 size, and wherein an effective amount of the pharmaceutical composition is administered to treat the disease or condition.
43. The method of claim 42, wherein the disease or condition comprises an allergy.
44. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof, wherein the liquid drug composition, upon intranasal administration to the subject by actuating a nasal spray device containing the liquid drug composition, forms a plume comprising more than one droplet, the more than one droplet passing through a D 90 wherein about 90% of the droplets in the plume have a diameter less than D 90 size, and wherein an effective amount of the pharmaceutical composition is administered to treat the disease or condition.
45. The method of claim 44, wherein the disease or condition comprises pain.
46. The method of claim 45, wherein the pain comprises acute pain or chronic pain.
47. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject an effective amount of a liquid pharmaceutical composition comprising: a) an anticholinergic drug or a salt thereof, and b) a pharmaceutically acceptable carrier, excipient, diluent, or any combination thereof, wherein the liquid drug composition, upon intranasal administration to the subject by actuating a nasal spray device containing the liquid drug composition, forms a plume comprising more than one droplet, the more than one droplet passing through a D 90 wherein about 90% of the droplets in the plume have a diameter less than D 90 size, and wherein an effective amount of the liquid pharmaceutical composition is administered to treat the disease or condition.
48. The method of claim 47, wherein the disease or condition comprises asthma, diarrhea, motion sickness, gastrointestinal disorders, overactive bladder, urinary incontinence, intoxication, muscle spasms, motion sickness, chronic obstructive pulmonary disease (COPD), hyperhidrosis, or any combination thereof.
Citation Information
Cited By
Application of recombinant human copper / zinc superoxide dismutase in preparation of medicine for preventing and treating allergic rhinitis
CN120837618A
